Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling

ABSTRACT

This invention provides a fusion protein comprising a signal peptide, EGF repeats 1-X of the extracellular domain of human Notch3 receptor protein wherein X is any integer from 12 to 34, and an Fc portion of an antibody bound thereto. This invention also provides a method for treating a subject having a tumor, a method for inhibiting angiogenesis in a subject, a method for treating a subject having ovarian cancer, and a method for treating a subject having a metabolic disorder, comprising administering to the subject an amount of the above fusion protein effective to treat the subject. This invention further provides uses of the above fusion protein for the preparation of a pharmaceutical composition for the treatment of a subject having a tumor, for inhibiting angiogenesis in a subject, for treating a subject having ovarian cancer, and for treating a subject having a metabolic disorder.

The invention disclosed herein was made with United States governmentsupport under grant number R01 HL62454 from the National Institutes ofHealth and grant number DAMRDCW81KWH-04-1-054 from the Department ofDefense. Accordingly, the United States government has certain rights inthis invention.

Throughout this application, various publications are referenced byarabic numbers within parentheses or by author and publication datewithin parentheses. Full citations for these publications may be foundat the end of the specification. The disclosures of these publicationsare hereby incorporated by reference into this application to describemore fully the art to which this invention pertains.

BACKGROUND OF THE INVENTION Vascular Development

During mammalian embryogenesis, formation of the vascular system is anearly and essential process. In the embryo, vascular developmentinitiates with the pluripotent hemangioblast derived from the paraxialand lateral plate mesoderm. The hemangioblast has the potential todifferentiate into either a hematopoietic progenitor or an endothelialcell progenitor, known as the angioblast.

Vascular development begins with a process known as vasculogenesiswhereby angioblasts differentiate into endothelial cells and migratetogether to form the primitive vascular plexus. This initial vascularnetwork consists of vessels that are homogenous in size and made upwholly of endothelial cells. The vascular plexus is then remodeled viaangiogenesis.

Angiogenesis involves the sprouting of new vessels, the migration ofthese vessels into avascular regions, and the recruitment of accessorycells, pericytes and smooth muscle cells (Gale and Yancopoulos, 1999).The smooth muscle cells that differentiate and form the contractilevessel walls originate from multiple progenitors including neural crestcells, mesenchymal cells and even endothelial cells (Owens, 1995). Inadults, angiogenesis is involved in follicular development, woundhealing, and pathological processes such as tumor angiogenesis and heartdisease.

The Notch Family and Notch Ligands

Studies of Drosophila, C. Elegans, zebrafish and mammals havedemonstrated that the Notch pathway is an evolutionarily conservedsignaling mechanism that functions to modulate numerous cell-fatedecisions. Notch signaling is required for the proper patterning ofcells originating from all three germ layers. Depending on the cellularcontext, Notch signaling may both inhibit and induce differentiation,induce proliferation, and promote cell survival (Artavanis-Tsakonas atal., 1995; Lewis, 1998; Weinmaster, 1997). In Drosophila, a single Notchprotein is activated by two ligands, Serrate and Delta. In mammals thesefamilies have been expanded to four Notch genes (Notch1, Notch2, Notch3and Notch4) and five ligands, 2 Serrate-like (Jagged1-2) and 3 Delta(Dl1, 3, 4) (Bettenhausen et al., 1995; Dunwoodie et al., 1997; Gallahanand Callahan, 1997; Lardelli et al., 1994; Lindsell et al., 1995;Shawber et al., 1996a; Shutter et al., 2000a; Uyttendaele et al., 1996;Weinmaster et al., 1992; Weinmaster et al., 1991). During embryogenesis,Notch receptors and ligands are expressed in dynamic spatial andtemporal patterns. However, it is not known if all ligands activate allreceptors.

Notch Signaling and Function

Notch signaling influences many different types of cell-fate decisionsby providing inhibitory, inductive or proliferative signals depending onthe environmental context (reviewed in Artavanis-Tsakonas et al., 1995;Greenwald, 1998; Robey, 1997; Vervoort et al., 1997). This pleiotropicfunction suggests that Notch modulates multiple signaling pathways in aspatio-temporal manner.

Consistent with Notch regulating cell-fate decisions, both the receptorsand ligands are cell surface proteins with single transmembrane domains(FIG. 1). The regulatory extracellular domain of Notch proteins consistslargely of tandemly arranged EGF-like repeats that are required forligand binding (Artavanis-Tsakonas et al., 1995; Weinmaster, 1998).C-terminal to the EGF-like repeats are an additional three cysteine-richrepeats, designated the LIN12/Notch repeats (LNR) (Greenwald, 1994).Downstream of the LNR lies the proteolytic cleavage sequence (RXRR) thatis recognized by a furin-like convertase. For Notch1, cleavage at thissite yields a 180 kilodalton extracellular peptide and a 120 kilodaltonintracellular peptide that are held together to generate a heterodimericreceptor at the cell surface (Blaumueller et al., 1997; Kopan et al.,1996; Logeat et al., 1998).

The intracellular domain of Notch (NotchICD, FIG. 1) rescuesloss-of-function Notch phenotypes indicating that this form of Notchsignals constitutively (Fortini and Artavanis-Tsakonas, 1993; Lyman andYoung, 1993; Rebay et al., 1993; Struhl et al., 1993).

The cytoplasmic domain of Notch contains three identifiable domains: theRAM domain, the ankyrin repeat domain and the C-terminal PEST domain(FIG. 1). Upon ligand-activation Notch undergoes two additionalproteolytic cleavages which results in the release of the cytoplasmicdomain (Weinmaster, 1998). This Notch peptide translocates to thenucleus and interacts with transcriptional repressors known as CSL (CBF,Su (H), Lag-2) and converts it to transcriptional activator. TheCSL/Notch interaction is dependent on the presence of the RAM domain ofNotch; while, transcriptional activity also requires the presence of theankyrin repeats (Hsieh et al., 1996; Hsieh at al., 1997; Roehl et al.,1996; Tamura et al., 1995; Wettstein et al., 1997). Both in vivo and invitro studies indicate that the HES and Hey genes are the direct targetsof Notch/CSL-dependent signaling (Bailey and Posakony, 1995; Eastman atal., 1997; Henderson et al., 2001; Jarriault et al., 1995; Nakagawa atal., 2000; Wettstein et al., 1997). The HES and Hey genes are bHLHtranscriptional repressor that bind DNA at N-boxes (Nakagawa et al.,2000; Sasai et al., 1992; Tietze et al., 1992). Notch has also beenproposed to signal by a CSL-independent pathway. In fact, expression ofjust the ankyrin repeat domain is necessary and sufficient for someforms of Notch signaling (Lieber et al., 1993; Matsuno et al., 1997;Shawber at al., 1996b).

Finally, the PEST domain has been implicated in protein turnover by aSEL-10/ubiquitin-dependent pathway (Greenwald, 1994; Oberg et al., 2001;Rogers et al., 1986; Wu et al., 1998; Wu et al., 2001). Similar to thereceptors, the extracellular domain of the Notch ligands also consistmostly of tandemly arranged EGF-like repeats (FIG. 1). Upstream of theserepeats is a divergent EGF-like repeat known as the DSL (Delta, Serrate,Lag-2) that is required for ligand binding and activation of thereceptors (Artavanis-Tsakonas et al., 1995).

Notch Signaling and Vascular Development

Although many of the genes that function to induce vasculogenesis andangiogenesis have been identified, little is known about how cell-fatedecisions are specified during vascular development. A number ofobservations suggest that the Notch signaling pathway may play a role incell fate determination and patterning of the vascular system.

Notch1, Notch4, Jagged1 and Dll4 are all expressed in the developingvasculature, while Notch3 is expressed in the accessory smooth musclecells (Krebs et al., 2000; Shutter et al., 2000b; Uyttendaele et al.,1996; Villa et al., 2001; Xue et al., 1999). Mice lacking Jagged1 areembryonic lethal and have severe vascular defects (Xue et al., 1999).Mice nullizygous for Notch1 are embryonic lethal and die of severeneuronal defects, but also have defects in angiogenesis (Krebs et al.,2000; Swiatek et al., 1994). Mice lacking Notch4 are born and appear tobe normal, but embryos that have lost both Notch1 and Notch4 die at E9.5of severe hemorrhaging and vascular patterning defects indicating Notch1and Notch4 may be functionally redundant during vascular development(Krebs et al., 2000). Exogenous expression of an activated form ofNotch4 in endothelium also resulted in vascular defects similar to thoseseen for the double Notch1/Notch4 nullizygous mice, suggesting thatappropriate levels of Notch signaling is critical for proper developmentof the embryonic vasculature (Uyttendaele et al., 2001).

Taken together, the data from mice mutant for Notch/Notch signalingcomponents uncover several processes dependent on Notch includingvascular remodeling, arterial venous specification, vascular smoothmuscle cell recruitment and heart/heart outflow vessel development.

Recent experiments have implicated Notch signaling in arterial/venousendothelial cell specification. In situ analysis of E13.5 embryos foundthat Notch1, Notch3, Notch4, Dl4, Jagged1 and Jagged2 expression wasrestricted to the arteries and absent in the veins (Villa et al., 2001).Consistent with expression data, disruption of Notch signaling inZebrafish was associated with loss of the arterial marker ephrinB2;while, ectopic expression of an activated form of Notch lead to a lossin the venous cell marker EphB4 within the dorsal aorta (Lawson et al.,2001). These data suggest that Notch signaling may help to specifyarterial and venous cell fates during angiogenesis.

Taken together, the data from mice mutant for Notch/Notch signalingcomponents uncover several processes dependent on Notch includingvascular remodeling, arterial venous specification, vascular smoothmuscle cell recruitment and heart/heart outflow vessel development.

Notch signaling has also been suggested to function in the adultvascular system. In humans, missense mutations in the extracellulardomain of Notch3 correlate with the development of the degenerativevascular disease, CADASIL (Caronti et al., 1998; Desmond et al., 1998;Joutel et al., 2000; Joutel et al., 1996). In a wound healing model, anincrease in Jagged1 expression was observed at the regeneratingendothelial wound edge, suggesting Notch signaling may function duringprocesses of adult angiogenesis (Lindner et al., 2001). Taken togetherthese data support Notch signaling functions at a number of criticalsteps during vascular development: vasculogenesis, vascularpatterning/angiogenesis, and arterial/venous specification. However, themolecular mechanism(s) by which the Notch signaling pathways influencethese different steps has yet to be elucidated.

Significance

-   Shimizu at al. (J. Biol. Chem. 274(46): 32961-32969 (1999)) describe    the use of Notch1ECD/Fc, Notch2ECD/Fc and Notch3ECD/Fc in binding    studies. However, Shimizu et al. do not mention the use of such    proteins for inhibiting angiogenesis.-   U.S. Pat. No. 6,379,925 issued Apr. 30, 2002 to Kitajewski et al.    describes murine Notch4. However, it does not describe Notch-based    fusion proteins as set forth in the subject application.

Notch proteins play key roles in developmental decisions involving thevasculature, the hematopoietic system, and the nervous system. As such,an understanding of their function is key to understanding how cell-fatedecisions and commitment are controlled during development and in adulttissues. To date, several reports on Notch or Notch ligand genedisruptions have described vascular phenotypes providing emphasis thatthis pathway is a fundamental part of the machinery that guides vasculardevelopment. Aberrant Notch activity has been linked to humanpathologies; including both cancer and vascular disorders (CADASIL). Theanalysis of Notch in tumor angiogenesis has only recently begun;however, our discovery of potential downstream targets of Notch suggestsa role in pathological processes associated with angiogenesis. Forinstance, VEGFR-3 has been linked to both tumor angiogenesis and tumorlymphangiogenesis. The expression or function of several other potentialNotch targets has also been linked to tumor angiogenesis; includingephrinB2, Id3, Angiopoietin 1, and PDGF-B. Insights on the role of thesetargets in Notch gene function will clearly facilitate future analysisof Notch in human pathologies.

SUMMARY OF THE INVENTION

This invention provides a fusion protein comprising a signal peptide,EGF repeats 1-x of the extracellular domain of human Notch3 receptorprotein wherein X is any integer from 12 to 34, and an Fc portion of anantibody bound thereto.

This invention provides a fusion protein comprising a signal peptide,EGF repeats 1-X of the extracellular domain of human Notch3 receptorprotein wherein X is any integer from 1 to 10, and an Fc portion of anantibody bound thereto.

This invention provides a fusion protein comprising a signal peptide, atleast 12 EGF repeats of the extracellular domain of human Notch3receptor, and an Fc portion of an antibody bound thereto.

This invention provides a fusion protein comprising a signal peptide,EGF repeats of the extracellular domain of human Notch3 receptorprotein, wherein at least 12 EGF repeats are present, and an Fc portionof an antibody bound thereto.

This invention provides a method for treating a subject having a tumorcomprising administering to the subject an amount of the above fusionprotein effective to treat the subject, thereby treating the subjecthaving a tumor.

This invention provides a method for inhibiting angiogenesis in asubject comprising administering to the subject an amount of the abovefusion protein effective to inhibit angiogenesis in the subject, therebyinhibiting angiogenesis in the subject.

This invention provides a method for treating a subject having ovariancancer comprising administering to the subject an amount of the abovefusion protein effective to treat the subject, thereby treating thesubject having ovarian cancer.

This invention provides use of the above fusion protein for thepreparation of a pharmaceutical composition for the treatment of asubject having a tumor.

This invention provides use of the above fusion protein for thepreparation of a pharmaceutical composition for inhibiting angiogenesisin a subject.

This invention provides use of the above fusion protein for thepreparation of a pharmaceutical composition for treating a subjecthaving ovarian cancer.

This invention provides use of the above fusion protein for thepreparation of a pharmaceutical composition for for treating a subjecthaving a metabolic disorder.

This invention provides a method for inhibiting physiologicallymphangiogenesis or pathological lymphangiogenesis in a subjectcomprising administering to the subject an amount of the above fusionprotein effective to inhibit physiological lymphangiogenesis orpathological lymphangiogenesis in the subject.

This invention provides a method of inhibiting tumor metastasis in asubject comprising administering to the subject an amount of the abovefusion protein effective to inhibit tumor metastasis in the subject.

This invention provides a method of inhibiting growth of a secondarytumor in a subject comprising administering to the subject an amount ofthe above fusion protein of effective to inhibit growth of the secondarytumor in the subject.

This invention provides a method of inhibiting blood vessel cooption bya tumor in subject comprising administering to the subject an amount ofthe above fusion protein effective to inhibit blood vessel cooption by atumor in the subject.

This invention provides a method of treating cancer in a subjectcomprising administering to the subject the above fusion protein and aninhibitor of Vascular Endothelial Growth Factor (VEGF), each in anamount effective to treat the cancer in the subject.

This invention provides a method of treating cancer in a subjectcomprising administering to the subject the above fusion protein and aVEGF receptor inhibitor, each in an amount effective to treat the cancerin the subject.

This invention provides a method of treating cancer in a subjectcomprising administering to the subject the above fusion protein and aninhibitor of Platelet Derived Growth Factor (PDGF), each in an amounteffective to treat the cancer in the subject.

This invention provides a method of treating cancer in a subjectcomprising administering to the subject the above fusion protein and aPDGF receptor antagonist, each in an amount effective to treat thecancer in the subject.

This invention provides a method of treating cancer in a subjectcomprising administering to the subject the above fusion protein and aninhibitor of HER2/neu, each in an amount effective to treat the cancerin the subject.

This invention provides a method of treating breast cancer in a subjectcomprising administering to the subject an amount of the above fusionprotein effective to treat the breast cancer in the subject.

This invention provides the use of the above fusion protein of for thepreparation of a pharmaceutical composition for treating a subjecthaving breast cancer.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1

This Figure shows the schematic structure of Notch and Notch ligands:Notch1, Notch2, Notch3, Notch4, Jagged-1, Jagged-2, Delta-like 1,Delta-like 3, Delta-like 4.

FIG. 2

This Figure shows the schematic design of Notch-based fusion proteins(NotchECD/Fc). The extracellular domain of Notch1, Notch2, Notch3, orNotch4 containing the EGF-repeats is fused to the Fc portion of anantibody.

FIG. 3

This Figure shows a co-culture assay for testing the activity ofNotch-based fusion proteins. Notch and Notch responsive transcriptionalreporters are expressed in a “Notch-responsive” cell, HeLa. Notchligands, Jagged-1, Delta-like 1, or Delta-like 4 are expressed in a“ligand-presenting” cell, 293. Expression is mediated by transfection ofindividual cell populations, cells are co-cultured, and then assayed forNotch-dependent reporter activity.

FIG. 4

This Figure shows the inhibitory activity of Notch-based fusion proteinagainst activation of Notch signaling by interaction between Notch andNotch ligand. Induction of Notch signaling was detected byco-cultivating both Notch1- and 3 types of Notch ligand-expressing cellsand these inductions were inhibited by co-transfection of Notch-basedfusion protein-expressing vector into Notch1-expressing cells.Therefore, Notch-based fusion proteins can be used as Notch inhibitorbased on inhibition of interaction between Notch and Notch ligand.

FIG. 5

This Figure shows the expression of Notch1-based fusion protein(Notch1ECD/Fc) in 293. Panel A: expression in cell lystates (lys) orsecreted into media (sup). Panel B: expression in 293 lysates ofNECD/Fcs, as listed.

FIG. 6

This Figure shows activation of Notch signaling in HUVEC infected withadenoviral-encoding VEGF-165. Activation of Notch signaling can bedetected by using CBF1 promoter activity. Transcriptional activity ofCBF1 promoter is activated by binding of Notch-IC to CBF1. We measuredCBF1 promoter activity in HUVEC which was infected withadenovirus-encoding VEGF-165 at different MOI. Induction of CBF1promoter was clearly detected in Ad-VEGF-infected HUVEC, compared toAd-LacZ-infected cells in the MOI dependent manner. This data showedoverexpression of VEGF could activate Notch signaling in HUVEC.

FIG. 7

This Figure shows the effect of Notch-based fusion proteins onVEGF-induced activation of Notch signaling. Co-infection ofAd-Notch-based fusion protein with Ad-VEGF clearly reduced activation ofCBF1 promoter activity induced by Ad-VEGF infection alone. In the caseof infection at 40 MOI for each adenovirus in panel A, 60% inhibition at24 hour and 90% inhibition at 48 hour after reporter gene transfectionwas detected. This inhibitory activity of Notch trap was dependent onMOI of Ad-Notch-based fusion protein.

FIG. 8

This Figure shows an experiment in which we evaluated the effect ofNotch-based fusion proteins on induction of budding by overexpressedVEGF-165 in HUVEC. When Ad-VEGF-infected HUVEC were cultured on typecollagen gel for 8 days, budding was induced into collagen gel. Thisinduction of budding by overexpressed VEGF was clearly inhibited bycoinfection of adenoviral-encoding Notch-based fusion proteins.Ad-Notch-based fusion protein itself had less effect on morphology.

FIG. 9

This Figure shows the result of counting buds per field undermicroscope. Ad-VEGF-infection into HUVEC increased the number of budsdepending on used MOI. Even though a half MOI of Notch-based fusionprotein was used, compared to Ad-VEGF, Ad-VEGF-induced budding wasclearly inhibited. These data suggested that VEGF induced budding ofHUVEC through activation of Notch signaling and Notch-based fusionprotein could inhibit VEGF-induced budding.

FIG. 10

This Figure shows the amino acid sequence of the extracellular domain ofthe rat Notch1 protein (SEQ ID NO:1) and a linker sequence (SEQ IDNO:2).

FIG. 11

This Figure shows the amino acid sequence of the extracellular domain ofthe rat Notch2 protein (SEQ ID NO:3) and a linker sequence (SEQ IDNO:2).

FIG. 12

This Figure shows the amino acid sequence of the extracellular domain ofthe mouse Notch3 protein (SEQ ID NO:4).

FIG. 13

This Figure shows the amino acid sequence of the extracellular domain ofthe mouse Notch4 protein (SEQ ID NO:5) and a linker sequence (SEQ IDNO:2).

FIGS. 14A and 14B

This Figure shows the nucleic acid sequence of the extracellular domainof the rat Notch1 gene (SEQ ID NO:6).

FIGS. 15A and 15B

This Figure shows the nucleic acid sequence of the extracellular domainof the rat Notch2 gene (SEQ ID NO:7).

FIGS. 16A and 16B

This Figure shows the nucleic acid sequence of the extracellular domainof the mouse Notch3 gene (SEQ ID NO:8).

FIGS. 17A and 17B

This Figure shows the nucleic acid sequence of the extracellular domainof the mouse Notch4 gene (SEQ ID NO:9) and the nucleic acid sequence(SEQ ID NO:10) and the amino acid sequence (SEQ ID NO:2) of a linkersequence.

FIGS. 18A and 18B

This Figure shows the nucleic acid sequence of the extracellular domainof the human Notch1 gene (SEQ ID NO:11).

FIGS. 19A and 19B

This Figure shows the nucleic acid sequence of the extracellular domainof the human Notch2 gene (SEQ ID NO:12).

FIGS. 20A and 20B

This Figure shows the nucleic acid sequence of the extracellular domainof the human Notch3 gene (SEQ ID NO:13).

FIGS. 21A and 21B

This Figure shows the nucleic acid sequence of the extracellular domainof the human Notch4 gene (SEQ ID NO:14).

FIGS. 22A-22I

These Figures show that VEGF activates Notch signaling to induce HUVECbudding. HUVEC were transduced with Ad-VEGF at 40 MOI (FIGS. 22A, 22H,22I) or 20 MOI (FIGS. 22C, 22G). Ad-LacZ was co-transduced to HUVEC tomake the same total amount of adenovirus 60 MOI (FIG. 22G), 80 MOI (FIG.22A) and 100 MOI (FIGS. 22H, 22I). FIG. 22A shows RT-PCR analysis ofNotch and Notch ligand expression. Numbers show PCR cycles. FIG. 22Bshows the effect of transduced VEGF on CSL reporter activity. FIG. 22Cshows the effect of SU5416 on CSL reporter activity transactivated byAd-VEGF. FIG. 22D shows the construct of Notch decoy (N1ECDFc). FIG. 22Eshows secretion of N1ECDFc from HUVEC trasduced with Ad-N1ECDFc. FIG.22F shows the effect of N1ECDFc against ligand-induced CSL reporteractivity in a co-culture assay (□: (−); ▪: 0.33 ng pHyTC-N1ECDFc; ▪:0.67 ng pHyTC-N1ECDFc). FIGS. 22G-I show the effect of N1ECDFc againstAd-VEGF-transduced HUVEC. Notch signaling was activated withtransduction of Ad-VEGF in HUVEC in the absence or presence ofco-transduction of Ad-N1ECDFc at indicated dosage. FIG. 22G shows theeffect of N1ECDFc on CSL reporter activity transactivated by Ad-VEGF.FIG. 22H shows inhibition of budding of Ad-VEGF-transduced HUVEC withco-transduction of Ad-N1ECDFc at 40 MOI. FIG. 22I shows quantificationof the effect of N1ECDFc on budding of Ad-VEGF-transduced HUVEC (□: bud;▪: cell number).

FIGS. 23A-23J

These Figures show that Notch signaling up-regulates Flt1 expression toinduce HUVEC budding. HUVEC were transduced with either Ad-LacZ orAd-N1IC at 40 MOI. FIGS. 23A-23C show the effect of inhibitors forreceptor tyrosine kinases on Notch-induced HUVEC budding. FIG. 23A is aphotograph of budding of Ad-N1IC-transduced HUVEC treated with PD166866,ZD1893 at 1 μm and SU5416 at 0.5 μm. FIG. 23B shows quantification ofthe effect of inhibitors at 1 μM (□: bud; ▪: cell number). FIG. 23Cshows dose-dependency of the effect of SU5416 (□: bud; ▪: cell number).FIGS. 23D-E show induction of Flt-1 expression in Ad-N1IC-transducedHUVEC. FIG. 23D shows RT-PCR analysis of Flt-1 mRNA expression. FIG. 23Eshows W. B. analysis of Flt-1 protein expression. FIGS. 23F-G showpromotion of Notch-induced HUVEC budding with P1GF stimulation.Ad-N1IC-transduced HUVEC were cultured on collagen gel with SFM, insteadof complete medium, in the absence or presence of 50 ng/ml P1GF. FIG.23F shows P1GF-induced budding of Ad-N1IC-transduces HUVEC (arrow head:buds with single filopodia; arrow: buds with multiple filopodia). FIG.23G shows the quantification of the effect of P1GF on budding ofAd-N1IC-transduced HUVEC (□: multi; ▪: total). FIGS. 23H-I show theeffect of Flt-1 siRNA transfection on Flt1 expression.Ad-N1IC-transduced HUVEC were transfected with 200 pmol of eithercontrol (CT) or Flt-1 siRNA. FIG. 23H shows the reduction of Flt-1 mRNAexpression. FIG. 23I shows the reduction of Flt-1 protein expression.FIG. 23J shows the effect of Flt-1 siRNA transfection on Notch-inducedHUVEC budding. Ad-N1IC-transduced HUVEC were transfected with either 100or 200 pmol of siRNA and cultured on collagen gel for 2 days.

FIGS. 24A-24E

These Figures show that VEGF regulates gelatinase activity via Notchsignaling by up-regulation of both MMP-9 and MT1-MMP. FIGS. 24A-B showgelatin zymography analysis of MMP-9 and MMP-2 activity stimulated byVEGF in HUVEC. FIG. 24A shows the effect of N1ECDFc on MMP-9 activity.Transduced HUVEC were cultured on fibrin gel on the indicated day (i.e.D2, D4, D6, D8). Similar results were also obtained by using collagengel, although induction of MMP-9 was stronger on fibrin gel thancollagen gel (data not shown). FIG. 24B shows the effect of N1ECDFc onMMP-2 activity. HUVEC were transduced with Ad-N1ECDFc at the indicateddoses and condition medium was collected from HUVEC cultured on collagengel at day 4. FIGS. 24C-D show up-regulation of MMP-9 and MT1-MMP withNotch signaling. HUVEC were transduced with either Ad-LacZ or Ad-N1IC at40 MOI. Numbers show PCR cycles. FIG. 24C shows RT-PCR analysis of theeffect of Notch signaling on expression of MMP-9 and MMP-2. FIG. 24Dshows the induction of MT1-MMP expression of both transcript and proteinwith Notch signaling. FIG. 24E shows RT-PCR analysis of MMP-9 andMT1-MMP expression in Ad-VEGF-HUVEC with co-transduction of Ad-N1ECDFc.HUVEC were transduced with Ad-VEGF in the absence or presence ofco-transduction of Ad-N1ECDFc at 40 MOI each. Ad-LacZ was co-transducedto make the same total amount of adenovirus at 80 MOI.

FIGS. 25A-25D

These Figures show the role of Notch signaling in VEGF-dependent in vivoangiogenesis. FIGS. 25A-25D show inhibition of VEGF-induced angiogenesiswith N1ECDFc in mouse DAS assay. Representative photographs are shown.FIG. 25A show subcutaneous induced angiogenesis with 293/VEGFtransfectant versus 293/VEGF also expressing Notch decoy (Notch-basedfusion protein) N1ECDFc. FIG. 25B shows the quantitation of degree ofvascularization induced by 293/VEGF in control versus 293 expressingNotch decoy (Notch-based fusion protein) N1ECDFc. FIG. 25C showssubcutaneous induced angiogenesis with Ad-LacZ infected MDA-MB-231 cellsversus Ad-N1ECDFc (Notch-based fusion protein) infected MDA-MB-231cells. MDA-MB-231 breast cancer cells produce VEGF (data not shown).FIG. 25D shows quantitation of degree of vascularization induced byAd-LacZ infected MDA-MB-231 cells versus Ad-N1ECDFc (Notch-based fusionprotein) infected MDA-MB-231 cells.

FIGS. 26A and 26B

These Figures show proliferation of Ad-VEGF165-transduced HUVEC. HUVECwere transduced with Ad-VEGF165 at the indicated dosages. Ad-LacZ wasalso co-infected to make the same total amount of adenovirus at a MOI of40 pfu/cell. HUVEC were suspended in SFM supplemented with 1% FBS andthen plated at 1×10⁴ cells/well in 24-well multi-wll plates with 0.4 mlof medium. After 4 days, cell numbers were determined using the CCK-8kit and the results are indicated as the ratio of cell numbersdetermined to the number of control cells, which were transduced withAd-GFP at a MOI of 40 pfu/cell. FIG. 26A shows the effect of transducedVEGF on proliferation. FIG. 26B shows the inhibitory effect of SU5416.Ad-VEGF-transduced HUVEC were treated with SU5416 at the indicateddosages.

FIGS. 27A and 27B

These Figures show the induction of HUVEC buds on type I collagen gel.HUVEC were transduced with either Ad-VEGF165 or AD-N1IC at the indicateddosages. Ad-LacZ was also co-infected to make the same total amount ofadenovirus at a MOI of 40 pfu/cell. Transduced HUVEC were cultured oncollagen gel with complete medium. The amount of budding was evaluatedunder microscopy at day 7.

FIGS. 28A and 28B

These Figures show the effect of alteration of Notch signaling on cellproliferation. The cells were transduced with the indicatedadenoviruses. Ad-GFP was also co-infected to make the same total amountof adenovirus at a MOI of 60 pfu/cell. After 4 days, cell numbers weredetermined using the CCK-8 kit and results are indicated as the ratio ofcell numbers determined to the number of control cells, which weretransduced with AD-GFP at MOI of 60 pfu/cell. FIG. 28A shows the effectof transduced N1IC and Notch fusion protein on the proliferation ofHUVEC. Transduced HUVEC were suspended in complete medium and thenplated at 1×10⁴ cells/well in 24-well multiwell plates with 0.4 ml ofindicated medium (□: Ad-N1IC; ▪: Ad-N1ECDFc). FIG. 28B shows the effectof Notch fusion protein on proliferation of KP1/VEGF transfectants.Transduced KP1/VEGF transfectants were suspended in RPMI1640 medium andthen plated at 2×10⁴ cells/well in 24-well multiwell plates with 0.5 mlof medium.

FIG. 29

This Figure shows the RT-PCR analysis of induction of PIGF expression inAd-N1IC-transduced HUVEC. HUVEC were infected with either Ad-LacZ orAd-N1IC at a MOI of 40 pfu/cell. Total RNA was isolated from transducedHUVEC cultured on collagen gel for 5 days with complete medium.

FIGS. 30A-30C

These Figures show inhibition of budding of either Ad-N1IC- orAd-VEGF-transduced HUVEC with Flk-1 siRNA transfection. FIG. 30A showsreduction of Flk-1 mRNA and protein expression in Ad-VEGF-HUVEC withtransfection of 200 pmol Flk-1 siRNA. Ad-VEGF-HUVEC at a MOI of 40pfu/cell were transfected with 200 pmol of either control (CT) or Flk-1siRNA. Total RNA was isolated 48 hours after transfection. Total celllysate was collected from serum starved cells with SFM for 48 hoursafter transfection. FIGS. 30B and 30C show the inhibitory effect ofFlk-1 siRNA transfection on either VEGF or Notch-induced HUVEC buds.Either Ad-N1IC- or Ad-VEGF-HUVEC at a MOI of 40 pfu/cell weretransfected with 200 pmol of siRNA as indicated and cultured on collagengel for 5 days. FIG. 30B shows the effect of Flk-1 siRNA transfection onHUVEC buds (□: Ad-VEGF; ▪: Ad-N1IC). FIG. 30C shows quantification ofthe inhibitory effect of Flk-1 siRNA transfection.

FIGS. 31A and 31B

These Figures show inhibition of budding of Ad-N1IC-transduced HUVECwith treatment of matrix metallo-proteinase inhibitor GM6001. EitherAd-LacZ or Ad-N1IC-HUVEC at a MOI of 40 pfu/cell were cultured oncollagen gel for 5 days in the absence or presence of GM6001 at 50 μm.FIG. 31A shows the effect of GM6001 on Notch-induced HUVEC buds. FIG.31B shows quantification of the inhibitory effect of GM6001.

FIGS. 32A, 32B and 32C:

This Figure shows the full-length nucleotide sequence of human Notch3(SEQ ID NO:15), consisting of the initiating ATG (nt 1) to the stop(TGA; nt 6964). The signal peptide and first 34 EGF-like repeat domainsare present in nt 1-4158 of this sequence. Nucleotides 1-4158 areutilized for the design of the human Notch3 decoy proteins, describedherein. The nucleotides encompassing EGF-repeats 1-34 are underlined.

FIG. 33:

This Figure shows the full-length amino acid (aa) sequence of humanNotch3 (SEQ ID NO:16), consisting of as 1(M=methionine) to as 2555(K=lysine). The signal peptide and first 34 EGF-like repeat domains arepresent in as 1-1386 of this sequence. Amino acids 1-1386 are utilizedfor the design of the human Notch3 decoy proteins, described in theensuing sections. The amino acids encompassing EGF-repeats 1-34 areunderlined.

FIG. 34

This figure shows the schematization of two human Notch3 decoy proteins,h-Notch3⁽¹⁻³⁴⁾decoy and h-sp^(HC)-Notch3⁽¹⁻³⁴⁾ decoy.

FIG. 35

This figure shows the human Fc nucleotide sequence utilized to generatethe Fc tag on Notch3 decoy proteins (SEQ ID NO:17). The 713 nucleotidesof human Fc are fused at the 3′-end of the Notch3 decoy construct, justdownstream of Notch3 EGF-like repeats. This region of human Fc allowsfor the detection and purification of the Notch decoys and serves tostabilize the secreted human Notch3-human Fc fusion proteins.

FIG. 36

This figure shows the human Fc amino acid sequence utilized to generatethe Fc tage on Notch3 decoy proteins (SEQ ID NO:18). The 237 amino acidsof human FC were fused at the C-terminus of all Notch3 decoy constructs,just downstream of the Notch3 EGF-like repeats. This region of human Fcallows for the detection and purification of the Notch decoys and servesto stabilize the secreted human Notch3-human Fc fusion proteins.

FIG. 37:

This figure shows the human Notch3/Fc fusion sequence for all constructsthat end after EGF repeat 34 of human Notch 3.

FIG. 38

This Figure shows the signal sequence analysis of human Notch3 signalpeptide that is predicted to encompass amino acids 1-40 of human Notch3.This determination was made using the signal IP 3.0 Server programprovided by the Technical University of Denmark. These results predict amajor site of cleavage located between alanine 39 (A39) and alanine 40(A40). The cleavage site is indivated by the “/” in amino acid sequence1-40 of human Notch3 as depicted in this figure.

FIG. 39:

This Figure shows the signal sequence analysis of human HC signalpeptide that is predicted to encompass amino acids 1-22 of human HC.This determination was made using the signal IP 3.0 Server programprovided by the Technical University of Denmark. These results predict amajor site of cleavage located between alanine 21 (A21) and aringine 22(A22). This cleavage site is indivated by the “/” in amino acid sequence1-22 of human HC provided above.

FIGS. 40A and 40B:

This Figure shows the nucleotide sequence of h-Notch3⁽¹⁻³⁴⁾ decoyprotein (SEQ ID NO:31). The predicted human Notch3 signal peptide isunderlined (nt 1-120). Notch3 EGF repeats 1-34 are encoded from nt121-4158. The fusion junction, BglII site, is located at nt 4158-4163.The Fc tag sequence is underlined and italicized.

FIG. 41

This Figure shows the amino acid sequence of h-Notch3⁽¹⁻³⁴⁾ decoyprotein (SEQ ID NO:32). The predicted human Notch3 signal peptide isunderlined (AA 1-40). Notch3 EGF repeats 1-34 are encoded from aa41-1386. The FC tag sequence is underlined and italicized.

FIG. 42

This Figure shows the amino acid sequence of h-sp^(HC)Notch3⁽¹⁻³⁴⁾ decoyprotein (SEQ ID NO:33). The predicted human Notch3 signal peptide isunderlined (AA 1-22). Notch3 EGF repeats 1-34 are encoded from aa22-1386. The FC tag sequence is underlined and italicized.

FIGS. 43A and 43B

This Figure shows the nucleotide sequence of h-sp^(HC)Notch3⁽¹⁻³⁴⁾ decoyprotein (SEQ ID NO:34). The predicted human HC signal peptide isunderlined (nt 1-66). Notch3 EGF-repeats are encoded from nt 67-4104.The fusion junction, BglII site, is from nt 5004 to 5009. The Fc tagsequence is underlined and italicized.

FIG. 44

This Figure shows expression of Notch proteins and ligands in blood andlymphatic endothelial cells. RT-PCT was performed for Notch1-4, Dll4,Dll4 and Jagged1 on RNA isolated from blood endothelial cells (BEC) andlymphatic endothelial cells (LEC) purified from HMVEC. Notch1, Notch1,Notch4, Dll4 and Jagged1 were expressed in both BEC and LEC at a similarlevel. Expression of Notch 3 appears to be restricted to the LECsuggestive of Notch3 signaling functions in the lymphatic endothelium.

FIG. 45

This Figure shows Notch3 is co-expressed with the lymphatic endothelialcell marker LYVE-1 and Prox1 in e13.5 embryos. 10 micron serial sectionsof embryonic day 13.5 mouse embryos were immunostained for eitherLYVE-1, Prox1 and Notch3. Notch3 was expressed in the cells that alsoexpressed the lymphatic endothelial cell markers, LYVE-1 and Prox1.

FIG. 46

This Figure shows Prox1 induced Notch3 expression in blood endothelialcells. (A) It was examined if extopic expression of Prox1 would alterthe expression of Notch proteins or ligands. Twenty-four hours postadenoviral infection with either Ad-Prox1 or Ad-LacZ, HUVEC total RNAwas isolated and quantitative RT-PCR for Notch1-4, Dll4 and Jagged1performed. Prox-1 robustly upregulated the expression of Notch3. Notch1,Notch2, Notch4, Dll4 and Jagged1 expression was not significantlyaffected. (B) Compound E (cE), Presenlin inhibitor that inhibits Notchsignaling, was incubated for 24 hours on either Ad-LacZ or Ad-Prox1infected HUVEC. Total RNA was isolated and quantitative PCR performed todetermine Notch3 expression. Prox1 induced Notch3 expression and thisinduction was inhibited by the addition of compound E. This suggeststhat the Prox1 induction of Notch3 is dependent on Notch signalactivation.

FIG. 47

This figure shows that Prox1 induces Notch-target genes in bloodendothelial cells. HUVEC were infected with adenoviruses encoding, LacZ,Prox1, N1IC or N4/int-3 and total RNA isolated 24 hours post-infection.Quantitative RT-PCR was performed for the endothelial Notch-targetgenes, VEGFR-3, EphrinB2, Hey1 and Hey2. Similar to Notch1 and Notch4signal activation, Prox1 induced all four genes (A and W. Expression ofHey1 and Hey2 in the lymphatic endothelium is unknown.

FIG. 48

This Figure shows that Prox1 induces Notch-target genes is dependent onNotch signaling in blood endothelial cells. HUVEC were infected withadenoviruses encoding LacZ, Prox1, N1Ic or N4/int-3. Compound E(cE),Presenlin inhibitor that inhibits Notch signaling, was incubated for 24hours on either Ad-LacZ or Ad-Prox1 infected HUVEC and total RNAisolated. Quantitative RT-PCR was performed for the endothelialNotch-target genes, VEGFR-3, EphrinB2, and Hey2. The Prox-1 mediatedinduction of the Notch target genes, ephrinB2, VEGFR-3 and Hey2 wasinhibited by the addition of the Notch signaling inhibitor Compound E.Thus, Prox1 regulates the expression of ephrinB2, VEGFR-3 and Hey2 viaNotch.

FIG. 49

This figure shows a Schematic of N1IC knock in. An activated form ofNotch1 was inserted into the EF1 alpha locus flanked by two LoxP sites.Upon expression of Cre-recombinase, the neo/tpA cassette is lost andN1IC is expressed under the control of the ubiquitous EF1 alphapromoter.

FIG. 50:

This Figure shows Notch activation in SM22 expressing vascular smoothmuscle cells results in embryonic lethality before E10.5. No viableSM22Cre/+; EF1αN1IC/mice were observed at postnatal day 21 (P21) with ap value less than 0.001. At embryonic day E9.5, an predicted number ofSM22Cre/+; EF1αN1IC/+ embryos were observed, but they were severelygrowth retarded compared with their control litter mates (Lower panel).

FIG. 51:

This Figure shows Notch activation in SM22 expressing vascular smoothmuscle cells alters alpha smooth muscle cell actin expression. E9.5embryos were wholemount immunostained for alpha smooth muscle cellactin. Expression of alpha smooth muscle cell actin was altered in theSM22Cre/+; EF1αN1IC/+ embryos compared to the WT controls. Thus, Notchsignal activation in vascular smooth muscle cells disruptscardiovascular development.

DETAILED DESCRIPTION OF THE INVENTION Terms

As used in this application, except as otherwise expressly providedherein, each of the following terms shall have the meaning set forthbelow.

“Administering” may be effected or performed using any of the methodsknown to one skilled in the art. The methods comprise, for example,intralesional, intramuscular, subcutaneous, intravenous,intraperitoneal, liposome-mediated, transmucosal, intestinal, topical,nasal, oral, anal, ocular or otic means of delivery.

“Affixed” shall mean attached by any means. In one embodiment, affixedmeans attached by a covalent bond. In another embodiment, affixed meansattached non-covalently.

“Amino acid,” “amino acid residue” and “residue” are usedinterchangeably herein to refer to an amino acid that is incorporatedinto a protein, polypeptide or peptide. The amino acid can be, forexample, a naturally occurring amino acid or an analog of a naturalamino acid that can function in a manner similar to that of thenaturally occurring amino acid.

“Antibody” shall include, without limitation, (a) an immunoglobulinmolecule comprising two heavy chains and two light chains and whichrecognizes an antigen; (b) a polyclonal or monoclonal immunoglobulinmolecule; and (c) a monovalent or divalent fragment thereof.Immunoglobulin molecules may derive from any of the commonly knownclasses, including but not limited to IgA, secretory IgA, IgG, IgE andIgM. IgG subclasses are well known to those in the art and include, butare not limited to, human IgG1, IgG2, IgG3 and IgG4. Antibodies can beboth naturally occurring and non-naturally occurring. Furthermore,antibodies include chimeric antibodies, wholly synthetic antibodies,single chain antibodies, and fragments thereof. Antibodies may be humanor nonhuman. Nonhuman antibodies may be humanized by recombinant methodsto reduce their immunogenicity in humans. Antibody fragments include,without limitation, Fab and F_(c) fragments. The “Fc portion of anantibody”, in one embodiment, is a crystallizable fragment obtained bypapain digestion of immunoglobulin that consists of the C-terminal halfof two heavy chains linked by disulfide bonds and known as the “effectorregion” of the immunoglobulin. In another embodiment, “Fc portion of anantibody” means all, or substantially all, of one C-terminal half of aheavy chain.

“Humanized”, with respect to an antibody, means an antibody whereinsome, most or all of the amino acids outside the CDR region are replacedwith corresponding amino acids derived from a human immunoglobulinmolecule. Small additions, deletions, insertions, substitutions ormodifications of amino acids are permissible as long as they do notabrogate the ability of the antibody to bind a given antigen. Suitablehuman immunoglobulin molecules include, without limitation, IgG1, IgG2,IgG3, IgG4, IgA and IgM molecules. Various publications describe how tomake humanized antibodies, e.g., U.S. Pat. Nos. 4,816,567, 5,225,539,5,585,089 and 5,693,761, and PCT International Publication No. WO90/07861.

As used herein, the term “composition”, as in pharmaceuticalcomposition, is intended to encompass a product comprising the activeingredient(s) and the inert ingredient(s) that make up the carrier, aswell as any product which results, directly or indirectly fromcombination, complexation, or aggregation of any two or more of theingredients, or from dissociation of one or more of the ingredients, orfrom other types of reactions or interactions of one or more of theingredients.

As used herein, “effective amount” refers to an amount which is capableof treating a subject having a tumor, a disease or a disorder.Accordingly, the effective amount will vary with the subject beingtreated, as well as the condition to be treated. A person of ordinaryskill in the art can perform routine titration experiments to determinesuch sufficient amount. The effective amount of a compound will varydepending on the subject and upon the particular route of administrationused. Based upon the compound, the amount can be delivered continuously,such as by continuous pump, or at periodic intervals (for example, onone or more separate occasions). Desired time intervals of multipleamounts of a particular compound can be determined without undueexperimentation by one skilled in the art. In one embodiment, theeffective amount is between about 1 μg/kg-10 mg/kg. In anotherembodiment, the effective amount is between about 10 μg/kg-1 mg/kg. In afurther embodiment, the effective amount is 100 μg/kg.

“Extracellular domain” as used in connection with Notch receptor proteinmeans all or a portion of Notch which (i) exists extracellularly (i.e.exists neither as a transmembrane portion or an intracellular portion)and (ii) binds to extracellular ligands to which intact Notch receptorprotein binds. The extracellular domain of Notch may optionally includea signal peptide. “Extracellular domain”, “ECD” and “Ectodomain” aresynonymous.

“Half-life-increasing moiety” means a moiety which, when operablyaffixed to a second moiety, increases the in vivo half-life of thesecond moiety. Half-life-increasing moieties include, for example, Fcportions of antibodies, glycosylation tags (i.e. glycosylatedpolypeptides), polyethylene glycol (PEG), polypeptides having PEGaffixed thereto, and lipid-modified polypeptides.

“Inhibiting” the onset of a disorder or undesirable biological processshall mean either lessening the likelihood of the disorder's or process'onset, or preventing the onset of the disorder or process entirely.

In the preferred embodiment, inhibiting the onset of a disorder orprocess means preventing its onset entirely.

“Notch”, “Notch protein”, and “Notch receptor protein” are synonymous.In addition, the terms “Notch-based fusion protein” and “Notch decoy”are synonymous. The following Notch amino acid sequences are known andhereby incorporated by reference: Notch1 (Genbank accession no. S18188(rat)); Notch2 (Genbank accession no. NP_(—)077334 (rat)); Notch3(Genbank accession no. Q61982 (mouse)); and Notch4 (Genbank accessionno. T09059 (mouse)). The following Notch nucleic acid sequences areknown and hereby incorporated by reference: Notch1 (Genbank accessionno. XM_(—)342392 (rat) and NM_(—)017617 (human)); Notch2 (Genbankaccession no. NM_(—)024358 (rat), M99437 (human and AF308601 (human));Notch3 (Genbank accession no. NM_(—)008716 (mouse) and XM_(—)009303(human)); and Notch4 (Genbank accession no. NM_(—)010929 (mouse) andNM_(—)004557 (human)).

The terms “nucleic acid”, “polynucleotide” and “nucleic acid sequence”are used interchangeably herein, and each refers to a polymer ofdeoxyribonucleotides and/or ribonucleotides. The deoxyribonucleotidesand ribonucleotides can be naturally occurring or synthetic analoguesthereof. “Nucleic acid” shall mean any nucleic acid, including, withoutlimitation, DNA, RNA and hybrids thereof. The nucleic acid bases thatform nucleic acid molecules can be the bases A, C, G, T and U, as wellas derivatives thereof. Derivatives of these bases are well known in theart, and are exemplified in PCR Systems, Reagents and Consumables(Perkin Elmer Catalogue 1996-1997, Roche Molecular Systems, Inc.,Branchburg, N.J., USA). Nucleic acids include, without limitation,anti-sense molecules and catalytic nucleic acid molecules such asribozymes and DNAzymes. Nucleic acids also include nucleic acids codingfor peptide analogs, fragments or derivatives which differ from thenaturally-occurring forms in terms of the identity of one or more aminoacid residues (deletion analogs containing less than all of thespecified residues; substitution analogs wherein one or more residuesare replaced by one or more residues; and addition analogs, wherein oneor more resides are added to a terminal or medial portion of thepeptide) which share some or all of the properties of thenaturally-occurring forms.

“Operably affixed” means, with respect to a first moiety affixed to asecond moiety, affixed in a manner permitting the first moiety tofunction (e.g. binding properties) as it would were it not so affixed.

The terms “polypeptide,” “peptide” and “protein” are usedinterchangeably herein, and each means a polymer of amino acid residues.The amino acid residues can be naturally occurring or chemical analoguesthereof. Polypeptides, peptides and proteins can also includemodifications such as glycosylation, lipid attachment, sulfation,hydroxylation, and ADP-ribosylation.

As used herein, “pharmaceutically acceptable carrier” means that thecarrier is compatible with the other ingredients of the formulation andis not deleterious to the recipient thereof, and encompasses any of thestandard pharmaceutically accepted carriers. Such carriers include, forexample, 0.01-0.1 M and preferably 0.05 M phosphate buffer or 0.8%saline. Additionally, such pharmaceutically acceptable carriers can beaqueous or non-aqueous solutions, suspensions, and emulsions. Examplesof non-aqueous solvents are propylene glycol, polyethylene glycol,vegetable oils such as olive oil, and injectable organic esters such asethyl oleate. Aqueous carriers include water, alcoholic/aqueoussolutions, emulsions and suspensions, including saline and bufferedmedia. Parenteral vehicles include sodium chloride solution, Ringer'sdextrose, dextrose and sodium chloride, lactated Ringer's and fixedoils. Intravenous vehicles include fluid and nutrient replenishers,electrolyte replenishers such as those based on Ringer's dextrose, andthe like. Preservatives and other additives may also be present, suchas, for example, antimicrobials, antioxidants, chelating agents, inertgases, and the like.

“Subject” shall mean any organism including, without limitation, amammal such as a mouse, a rat, a dog, a guinea pig, a ferret, a rabbitand a primate. In the preferred embodiment, the subject is a humanbeing.

“Treating” means either slowing, stopping or reversing the progressionof a disease or disorder. As used herein, “treating” also means theamelioration of symptoms associated with the disease or disorder.Diseases include, but are not limited to, Tumor Angiogenesis,Atherosclerosis, Wound Healing, Macular degeneration, Retinopathy ofPrematurity, Pre-eclampsia, Diabetic retinopathy, Ischemia, Stroke,Cardiovascular Disease, and Psoriasis.

Angiogenesis is encountered during wound healing processes, the femalemenstrual cycle and endometrial remodeling, as well as during embryonicdevelopment and organ growth. In the pathological setting, angiogenesisplays an important role in different diseases like rheumatoid arthritis,psoriasis, macular degeneration, diabetic retinopathy, and tumor growth.

There has been considerable evidence in vivo, including clinicalobservations, that abnormal angiogenesis is implicated in a number ofdisease conditions, which include rheumatoid arthritis, inflammation,cancer, psoriasis, degenerative eye conditions and others.

Units, prefixes and symbols may be denoted in their SI accepted form.Unless otherwise indicated, nucleic acid sequences are written left toright in 5′ to 3′ orientation and amino acid sequences are written leftto right in amino- to carboxy-terminal orientation. Amino acids may bereferred to herein by either their commonly known three letter symbolsor by the one-letter symbols recommended by the IUPAC-IUB BiochemicalNomenclature Commission. Nucleotides, likewise, may be referred to bytheir commonly accepted single-letter codes.

The following abbreviations are used herein: ECD: extracellular domain;IC: intracellular domain; NECD/Fc: Notch-based fusion protein; N1:Notch1; N2: Notch2; N3: Notch3; N4: Notch4; Dll: Delta-like; EC:endothelial cells; FGF: fibroblast growth factor; FGFR: fibroblastgrowth factor receptor; HUVEC: human umbilical vein endothelial cell;m.o.i.: multiplicity of infection; VMC: vascular mural cells; VEGF:vascular endothelial cell growth factor; VEGFR: vascular endothelialcell growth factor receptor; sp: signal peptide.; HC or Hc: Heavy ChainIgG; PDGF: Platelet derived growth factor; P1GF: placental growthfactor;

EMBODIMENTS OF THE INVENTION

This invention provides a fusion protein comprising a signal peptide,EGF repeats 1-X of the extracellular domain of human Notch3 receptorprotein wherein X is any integer from 12 to 34, and an Fc portion of anantibody bound thereto.

This invention provides a fusion protein comprising a signal peptide,EGF repeats 1-X of the extracellular domain of human Notch3 receptorprotein wherein X is any integer from 1 to 10, and an Fc portion of anantibody bound thereto.

This invention provides a fusion protein comprising a signal peptide, atleast 12 EGF repeats of the extracellular domain of human Notch3receptor, and an Fc portion of an antibody bound thereto.

This invention provides a fusion protein comprising a signal peptide,EGF repeats of the extracellular domain of human Notch3 receptorprotein, wherein at least 12 EGF repeats are present, and an Fc portionof an antibody bound thereto.

In one embodiment of the fusion protein, the extracellular domain ofNotch3 receptor protein comprises EGF-like repeats 1-34.

In one embodiment of the dusion protein, the Fc portion of the antibodyis the Fc portion of a human antibody.

In one embodiment of the fusion protein, the signal peptide is thesignal peptide of Notch3 or the He (HC; Heavy Chain) portion of anantibody.

In one embodiment, the fusion protein comprises consecutive amino acids,the sequence of which is set forth in SEQ ID NO:32. In anotherembodiment, the fusion protein comprises consecutive amino acids, thesequence of which is set forth in SEQ ID NO:33.

In one embodiment, the fusion protein is encoded by consecutivenucleotide, the sequence of which is set forth in SEQ ID NO:31. Inanother embodiment, the fusion protein is encoded by consecutivenucleotide, the sequence of which is set forth in SEQ ID NO:34

This invention provides a method for treating a subject having a tumorcomprising administering to the subject an amount of the above fusionprotein effective to treat the subject, thereby treating the subjecthaving a tumor.

This invention provides a method for inhibiting angiogenesis in asubject comprising administering to the subject an amount of the abovefusion protein effective to inhibit angiogenesis in the subject, therebyinhibiting angiogenesis in the subject.

This invention provides a method for treating a subject having ovariancancer comprising administering to the subject an amount of the abovefusion protein effective to treat the subject, thereby treating thesubject having ovarian cancer.

This invention provides use of the above fusion protein for thepreparation of a pharmaceutical composition for treating a subjecthaving cardiovascular disease. In one embodiment the cardiovasculardisease is atherosclerosis, ischemia or stroke.

This invention provides use of the above fusion protein for thepreparation of a pharmaceutical composition for the treatment of asubject having a tumor.

This invention provides use of the above fusion protein for thepreparation of a pharmaceutical composition for inhibiting angiogenesisin a subject.

This invention provides use of the above fusion protein for thepreparation of a pharmaceutical composition for treating a subjecthaving ovarian cancer.

This invention provides a method for inhibiting physiologicallymphangiogenesis or pathological lymphangiogenesis in a subjectcomprising administering to the subject an amount of the above fusionprotein effective to inhibit physiological lymphangiogenesis orpathological lymphangiogenesis in the subject. In one embodiment thepathological lymphangiogenesis is tumor lymphangiogenesis or lymph nodemetastasis that may be dependent on tumor lymphangiogenesis.

This invention provides method of inhibiting tumor metastasis in asubject comprising administering to the subject an amount of the abovefusion effective to inhibit tumor metastasis in the subject. In onembodiment, the metastasis occurs via a blood vessel, the lymphaticvasculature or a lymph node. Tumor metastasis is the spread of cancerfrom one organ to another non-adjacent organ.

This invention provides a method of inhibiting growth of a secondarytumor in a subject comprising administering to the subject an amount ofthe above fusion protein effective to inhibit growth of the secondarytumor in the subject. Inhibition may also be of the tumor angiogenesisassociated with the secondary or metastatic tumor. In one embodiment thesecondary tumor growth is inhibited by inhibition of angiogenesisassociated with the secondary tumor.

This invention provides a method of inhibiting blood vessel cooption bya tumor in subject comprising administering to the subject an amount ofthe above fusion protein effective to inhibit blood vessel cooption by atumor in the subject. The process of vessel cooption is a processwhereby tumor cells associate with pre-existing vessels and growth withassistance of coopted vessels. This growth of tumors on coopted vesselsmay be in the absence of, precede, or be in conjunction with tumorangiogenesis.

This invention provides a method of treating cancer in a subjectcomprising administering to the subject the above fusion protein and aninhibitor of Vascular Endothelial Growth Factor (VEGF), each in anamount effective to treat the cancer in the subject. In one embodimentthe inhibitor of VEGF is an inhibitor of VEGF-A, an inhibitor of PGIF,an inhibitor of VEGF-B, an inhibitor of VEGF-C, or an inhibitor ofVEGF-D. Examples of VEGF-inhibitors include, but are not limited to,bevacizumab, PTK787, Bay43-9006, SU11248, AG013676, ZD6474, VEGF-trapand Anti-VEGFR2. Examples of such inhibitors are more fully described inFerrara et al., (2004) Nature Reviews Drug Discovery, Vol. 3:391-400 andEllis et al. (2008) Nature Reviews Cancer Vol 8:579-591, the contents ofeach of which are hereby incorporated by reference.

This invention provides a method of treating cancer in a subjectcomprising administering to the subject the above fusion protein and aVEGF receptor inhibitor, each in an amount effective to treat the cancerin the subject. In one embodiment, the VEGF receptor inhibitor is aVEGFR-1 inhibitor, a VEGFR-2 inhibitor, a VEGFR-3 inhibitor or a aninhibitor of any combination of VEGFRs.

This invention provides a method of treating cancer in a subjectcomprising administering to the subject the above fusion protein and aninhibitor of Platelet Derived Growth Factor (PDGF), each in an amounteffective to treat the cancer in the subject. In on embodiment theinhibitor of Platelet Derived Growth Factors is an inhibitor of PDGF-Aor an inhibitor of PDGF-B

This invention provides a method of treating cancer in a subjectcomprising administering to the subject the above fusion protein and aPDGF receptor antagonist, each in an amount effective to treat thecancer in the subject. In one embodiment the PDGF receptor antagonist isa PDGF Receptor-B antagonist.

This invention provides a method of treating cancer in a subjectcomprising administering to the subject the above fusion protein and aninhibitor of HER2/neu, each in an amount effective to treat the cancerin the subject.

This invention provides a method of treating breast cancer in a subjectcomprising administering to the subject an amount of the above-fusionprotein effective to treat the breast cancer in the subject.

This invention provides the use of the above fusion protein for thepreparation of a pharmaceutical composition for treating a subjecthaving breast cancer.

This invention also provides a first method for treating a subjecthaving a tumor comprising administering to the subject an effectiveamount of a composition of matter comprising the extracellular domain ofa Notch receptor protein operably affixed to a half-life-increasingmoiety, so as to thereby treat the subject.

This invention also provides a second method for inhibiting angiogenesisin a subject comprising administering to the subject an effective amountof a composition of matter comprising the extracellular domain of aNotch receptor protein operably affixed to a half-life-increasingmoiety, so as to thereby inhibit angiogenesis in the subject.

In a first embodiment of the above methods, the Notch receptor proteinis Notch1 receptor protein. In one embodiment, the Notch1 receptorprotein is human Notch1 receptor protein. In another embodiment, thehalf-life-increasing moiety is an Fc portion of an antibody. In anotherembodiment, the Fc portion of the antibody is the Fc portion of a humanantibody. In a further embodiment, the extracellular domain and thehalf-life-increasing moiety are within the same polypeptide chain.

In a second embodiment of the above methods, the Notch receptor proteinis Notch2 receptor protein. In one embodiment, the Notch2 receptorprotein is human Notch2 receptor protein. In another embodiment, thehalf-life-increasing moiety is an Fc portion of an antibody. In anotherembodiment, the Fc portion of the antibody is the Fc portion of a humanantibody. In a further embodiment, the extracellular domain and thehalf-life-increasing moiety are within the same polypeptide chain.

In a third embodiment of the above methods, the Notch receptor proteinis Notch3 receptor protein. In one embodiment, the Notch3 receptorprotein is human Notch3 receptor protein. In another embodiment, thehalf-life-increasing moiety is an Fc portion of an antibody. In anotherembodiment, the Fc portion of the antibody is the Fc portion of a humanantibody. In a further embodiment, the extracellular domain and thehalf-life-increasing moiety are within the same polypeptide chain.

In a fourth embodiment of the above methods, the Notch receptor proteinis Notch4 receptor protein. In one embodiment, the Notch4 receptorprotein is human Notch4 receptor protein. In another embodiment, thehalf-life-increasing moiety is an Fc portion of an antibody. In anotherembodiment, the Fc portion of the antibody is the Fc portion of a humanantibody. In a further embodiment, the extracellular domain and thehalf-life-increasing moiety are within the same polypeptide chain.

In a fifth embodiment of the above methods, the subject is a mammal. Inone embodiment, the mammal is a human.

In a sixth embodiment of the above methods, the angiogenesis is tumorangiogenesis.

In a further embodiment of the second method, the subject has a tumor.In another embodiment, the subject is afflicted with a pathologicvascular hyperplasia. In one embodiment, the pathologic vascularhyperplasia is a benign hemagioma. In a further embodiment, the subjectis afflicted with a lymphatic vascular proliferative disease.

This invention provides a first composition of matter comprising theextracellular domain of Notch4 receptor protein operably affixed to ahalf-life-increasing moiety. In one embodiment, the extracellular domainis covalently bound to the half-life-increasing moiety. In anotherembodiment, the extracellular domain and the half-life-increasing moietyare within the same polypeptide chain.

This invention also provides a second composition of matter comprisingthe extracellular domain of Notch4 receptor protein operably affixed toa half-life-increasing moiety and a pharmaceutically acceptable carrier.

This invention further provides an article of manufacture comprising (i)a packaging material having therein a composition of matter comprisingthe extracellular domain of a Notch receptor protein operably affixed toa half-life-increasing moiety and (ii) a label indicating that thecomposition is intended for use in treating a subject having a tumor orother disorder treatable by inhibiting angiogenesis in the subject.

In a first embodiment of the above article, the Notch receptor proteinis Notch1 receptor protein. In one embodiment, the Notch1 receptorprotein is human Notch1 receptor protein. In another embodiment, thehalf-life-increasing moiety is an Fc portion of an antibody. In anotherembodiment, the Fc portion of the antibody is the Fc portion of a humanantibody. In a further embodiment, the extracellular domain and theHalf-life-increasing moiety are within the same polypeptide chain.

In a second embodiment of the above article, the Notch receptor proteinis Notch2 receptor protein. In one embodiment, the Notch2 receptorprotein is human Notch2 receptor protein. In another embodiment, thehalf-life-increasing moiety is an Fc portion of an antibody. In anotherembodiment, the Fc portion of the antibody is the Fc portion of a humanantibody. In a further embodiment, the extracellular domain and theHalf-life-increasing moiety are within the same polypeptide chain.

In a third embodiment of the above article, the Notch receptor proteinis Notch3 receptor protein. In one embodiment, the Notch3 receptorprotein is human Notch3 receptor protein. In another embodiment, thehalf-life-increasing moiety is an Fc portion of an antibody. In anotherembodiment, the Fc portion of the antibody is the Fc portion of a humanantibody. In a further embodiment, the extracellular domain and theHalf-life-increasing moiety are within the same polypeptide chain.

In a fourth embodiment of the above article, the Notch receptor proteinis Notch4 receptor protein. In one embodiment, the Notch4 receptorprotein is human Notch4 receptor protein. In another embodiment, thehalf-life-increasing moiety is an Fc portion of an antibody. In anotherembodiment, the Fc portion of the antibody is the Fc portion of a humanantibody. In a further embodiment, the extracellular domain and theHalf-life-increasing moiety are within the same polypeptide chain.

In another embodiment of the above article, the composition is admixedwith a pharmaceutical carrier. In a final embodiment, the subject is ahuman.

This invention provides a replicable vector which encodes a polypeptidecomprising the extracellular domain of a Notch3 receptor proteinoperably affixed to a half-life-increasing moiety. In one embodiment,the half-life-increasing moiety is an Fc portion of an antibody. Inanother embodiment, the vector includes, without limitation, a plasmid,a cosmid, a retrovirus, an adenovirus, a lambda phage or a YAC.

This invention also provides a host vector system which comprises areplicable vector which encodes a polypeptide comprising theextracellular domain of a Notch receptor protein operably affixed to ahalf-life-increasing moiety and a suitable host cell. In one embodiment,the host cell is a eukaryotic cell. In another embodiment, theeukaryotic cell is a CHO cell. In a another embodiment, the eukaryoticcell is a HeLa cell. In a further embodiment, the host cell is abacterial cell.

Finally, this invention provides a third method of producing apolypeptide which comprises growing a host vector system which comprisesa replicable vector which encodes a polypeptide comprising theextracellular domain of a Notch receptor protein operably affixed to ahalf-life-increasing moiety and a suitable host cell under conditionspermitting production of the polypeptide, and recovering the polypeptideso produced.

This invention is illustrated in the Experimental Details section whichfollows. This section is set forth to aid in an understanding of theinvention but is not intended to, and should not be construed to, limitin any way the invention as set forth in the claims which followthereafter.

EXPERIMENTAL DETAILS First Series of Experiments Human Notch3 FusionProteins (Notch Decoys)

The Notch3 decoys are assembled using sequences encoding a signalpeptide, a portion of the Notch3 extracellular domain encompassing allthe EGF-like repeat domains, and a portion of the human Fc protein(amino acids 1-237). The complete full-length nucleotide sequence ofhuman Notch3 is provided in FIG. 32. The complete full length amino acidsequence of human Notch3 is provided in FIG. 33.

The signal peptides utilized are either the native Notch3 signal peptideor the human Hc signal peptide, each fused to a region of Notch3. Thesignal peptide allows for secretion of the Notch decoy proteins.

The Notch3 extracellular domains used are designed to bind to Notchligands and consist of all or a subset of the 34 EGF-like repeat domainsof the human Notch3 protein.

The Fc tag is fused to the C-terminus of a given EGF-like repeat ofhuman Notch3 and serves to allow for purification, detection, andstabilization of the Notch3 decoy proteins.

The overall design of the human Notch3 decoys, two formulations, is toencode for; (1) a signal peptide to allow for secretion of Notch3 decoyproteins into the extracellular media of eukaryotic cells that are usedto produce the proteins,(2) a portion of the extracellular domain of allthe EGF-like repeats of human Notch3 to allow for association with Notchligands, and (3) a portion of the human Fc protein to allow fordetection.

The following two formulations of human Notch3 decoys will be describedand are schematized in FIG. 34.

h-Notch3⁽¹⁻³⁴⁾decoy  1)

h-sp^(Hc)Notch3⁽¹⁻³⁴⁾decoy  4)

Human Notch3 Sequence

The full-length nucleotide (nt) sequence of human Notch3, consisting ofthe initiating ATG (nt 1) to the stop (TGA; nt 6964) is set forth inFIG. 32. The signal peptide and first 34 EGF-like repeat domains arepresent in nt 1-4158 of this sequence. Nucleotides 1-4158 are utilizedfor the design of the human Notch3 decoy proteins, described in theensuing sections. The nucleotides encompassing EGF-repeats 1-34 areunderlined.

The full-length amino acid (aa) sequence of human Notch3, consisting ofas 1(M=methionine) to as 2555 (K=lysine) is set forth in FIG. 33. Thesignal peptide and first 34 EGF-like repeat domains are present in as1-1386 of this sequence. Amino acids 1-1386 are utilized for the designof the human Notch3 decoy proteins, described in the ensuing sections.The amino acids encompassing EGF repeats 1-34 are underlined.

Human Fc Sequence Utilized to Generate the Fc Tag on Notch3 decoyproteins

The 713 nucleotides of human Fc, which are set forth in FIG. 35, arefused at the 3′-end of the Notch3 decoy construct, just downstream ofNotch3 EGF-like repeats. This region of human fc allows for detectionand purification of the Notch decoys and serves to stabilize thesecreted human Notch3-human Fc fusion proteins.

The 237 amino acids of human Fc, shown in FIG. 36, were fused at theC-terminus of all Notch3 decoy constructs, just downstream of Notch3EGF-like repeats. This region of human Fc allows for detection andpurification of the Notch decoys and serves to stabilize the secretedhuman Notch3-human Fc fusion proteins.

Signal Peptides Utilized in Notch3 Decoy Proteins

Two distinct signal peptide sequences were incorporated into the designof the human Notch1 decoy proteins. The first is the human Notch3 signalpeptide that is predicted to encompass amino acids 1-40 of human Notch3.This determination was made using the Signal IP 3.0 Server programprovided by the Technical University of Denmark. The second is the humanHc signal peptide that is predicted to encompass amino acids 1-22 ofhuman IgG heavy chain (HC) signal peptide.

1. Human Notch3 Signal Peptide (nt 1-20)

(SEQ ID NO: 27) MGPGARGRRRRRRPMSPPPPPPPVRALPLLLLLAGPGAA/A

Amino acid sequence of the predicted human Notch3 signal peptide isschematized in FIG. 37. The prediction results of analysis utilizing theSignalIP 3.0 Server provided online by the Technical University ofDenmark are shown in FIG. 37. These results predict a major site ofcleavage located between alanine 39 (A39) and alanine 40 (A40) Thesecleavage site is indicated by the “/” in amino acid sequence 1-40 ofhuman Notch3, provided above.

2. Human HC Signal Peptide (aa 1-22)

The amino acid sequence of the predicted human Hc signal peptide is

MWGWECLLFWAVLVTATLCTA/R (SEQ ID NO: 29)

The nucleotide sequence of the predicted human Hc signal peptide is:

The prediction results of analysis utilizing the SignalIP 3.0 Serverprovided online by the Technical University of Denmark are shown above.These results predict a major site of cleavage located between alanine21 (A21) and arginine 22 (22). This cleavage site is indicated by the“/” in amino acid sequence 1-22 of human Hc provided above.

h-Notch3⁽¹⁻³⁴⁾ Decoy

h-Notch1⁽¹⁻³⁴⁾ decoy denotes the human Notch3 decoy that encompassEGF-like repeats 1-34 of Notch3.

The amino acid sequence of h-Notch3⁽¹⁻³⁴⁾ decoy protein which is setforth in FIG. 41. The predicted human Notch3 signal peptide isunderlined (AA 1-40). Notch3 EGF-repeats 1-34 are encoded from as41-1386. The Fc tage sequence is underlined and italicized.

The nucleotide sequence of h-Notch3⁽¹⁻³⁴⁾ decoy protein which is setforth in FIG. 40. The predicted human Notch3 signal peptide isunderlined (nt 1-120). Notch3 EGF repeats 1-34 are encoded from nt121-4158. The fusion junction, BglII site is nt 4158 to 4163. The Fctage sequence is underlined and italicized.

h-sp^(Hc)Notch1⁽¹⁻³⁴⁾ Decoy

h-sp^(Hc)Notch1⁽¹⁻³⁴⁾ decoy denotes the human Notch3 decoy thatencompass EGF-like repeats 1-34. The abbreviation sp^(Hc) denotes thatthe human Hc signal peptide is used in this formulation.

The amino acid sequence of h-Notch3⁽¹⁻³⁴⁾ decoy protein which is setforth in FIG. 42. The predicted human Hc signal peptide is underlined(AA 1-22). Notch3 EGF-repeats 1-34 are encoded from as 22-1386. The Fctag sequence is underlined and italicized.

The nucleotide sequence of h-Notch3⁽¹⁻³⁴⁾ decoy protein which is setforth in FIG. 43. The predicted human Hc signal peptide is underlined(nt 1-66). Notch3 EGF repeats 1-34 are encoded from nt 67-4104. Thefusion junction, BglII site is nt 4104 to 4109. The Fc tag sequence isunderlined and italicized.

Methods Construction of Human Notch3 Decoys

Total RNA from either human aortic smooth muscle cells (AoSMC) or humanumbilical venous endothelial cells (HUVEC) that overexpress Prox1 wereused to generate human Notch3 decoy variants. Total RNA was reversetranscribed with M-MLV reverse transcriptase and either random hexamerprimers or Notch3 decoy specific primers. The synthesized cDNA was thenamplified with Notch3 decoy specific upstream (sense) and downstream(antisense) primers. The Notch3 decoy was constructed from 4 individualamplicons. The 3-prime amplicon was amplified with a downstream primerencoding a Bgl II restriction site at the 5-prime end for ligation intothe BglII site in the Fc sequence to generate an in fram human Notch3/Fcchimera.

In the case of Notch3 decoys that generate the fusion after nucleotidesequence encoding EGF-like repeat 34, a BglIII site will be generated tocreate the fusion site and this fusion sequence is provided (Notch3,FIG. 37).

This applies to formulations h-Notch3(1-34)decoy and h-sp^(HC)Notch3(1-34) decoy.

The amplified PCR products were subcloned into e pBluescript SK II Fc togenerate the different human Notch3/Fc chimeras. The human Notch3/Fcdecoy sequences are then shuttled into mammalian expression vectors(pAd-lox, pCCL or pcDNA3) for expression and purification of humanNotch3 decoy proteins.

Second Series of Experiments Materials & Methods Plasmid Constructs

Adenovirus constructs encoding LacZ, full-length Notch4, or theactivated form of Notch4/int3 have been previously described (Shawber etal., 2003). An activated form of Notch1 cDNA fused in frame with 6 myctags (Kopan et al., 1994) was cloned into the adenovirus expressionvector, pAd-lox. Both VEGF165 and N1ECDFc was also cloned into thepAd-lox. Adenoviral stocks were generated and titered as previouslydescribed (Hardy et al., 1997). The retroviral expression vector pHyTCencoding either LacZ, the activated form of Notch4/int3, J1, Dll1 andDll4 have been previously described (Uyttendaele et al., 2000, Shawberet al., 2003, Das et al., 2004 in print). Plasmids encoding theintracellular domain of Notch1 (bp 5479-7833, Genbank accession# X57405)and the extracellular domain of Dll4 (bp 1-1545, Genbank accession#AF253468, provided by Chiron) fused in frame with a myc/His tag, wereengineered into pHyTC.

Notch1ECD, Notch2ECD, Notch3ECD and Notch4ECD are engineered into the Fccontaining plasmid pCMX-sFR1-IgG using the methods set forth in Clin.Exp. Immunol. (1992) 87(1):105-110 to create the Notch-based fusionproteins, i.e. Notch1ECD/Fc, Notch2ECD/Fc, Notch3ECD/Fc andNotch4ECD/Fc.

Adenoviral Gene Transfer 7.5×10⁵ cells of HUVEC at passage 3 were seededinto type I collagen-coated 6 well plates on the day before adenoviralinfection. Adenoviral infection with Ad-lacZ, Ad-VEGF165 or Ad-N1ECDFcwas performed at indicated m.o.i., and incubated at 37° C. for 1 hr withoccasional swirling of plates.

Luciferase Reporter Assays

To determine ligand-induced Notch signaling, co-culture assays wereperformed using HeLa and 293-derived Bosc cells. Transient transfectionswere performed by calcium phosphate precipitation. Hela cells plated1-day prior in 10-cm plates at 1.5×10⁶ were transfected with 333 ng ofpBOS Notch1, 333 ng pGA981-6, and 83 ng pLNC lacZ with either 666 ngpCMV-Fc or pHyTC-N1ECDFc (333 ng for x1, 666 ng for x2). Bosc cellsplated 1-day prior in 10-cm plates at 4×10⁶ were transfected with either680 ng pHyTc-Jagged1, pHyTc-Dll1, pHyTc-Dll4, or pHyTc-x (empty vector).One day after transfection, the cells were co-cultured in triplicate(HeLa:Bosc, 1:2) on 12-well plates for 24 hours. Cells were harvestedand luciferase activity was determined 2-days post-transfection usingthe Enhanced Luciferase assay kit (BD PharMingen), and 3-galactosidaseactivity was determined using the Galacto-Light Plus kit (PEBiosystems). All assays were performed in a Berthold dual-injectionluminometer.

To determine VEGF-induced Notch signaling, HUVEC which were infectedwith adenovirus were used. HUVEC plated 1-day prior in 6 well plates at8.0×10⁵ were infected with either Ad-LacZ as control or Ad-VEGF atindicated m.o.i. in the presence or absence of Ad-N1ECD/Fc. Two daysafter infection, infected HUVEC were re-seeded into 24-well plate at1.5×10⁵ cell in triplicate and cultured for 24 hours, and thentransfected with 12.5 ng pRL-SV40 (Promega) and 137.5 ng pGA981-6 usingEffectene transfection reagent (Qiagen). Cells were harvested either 1or 2 days post-transfection and luciferase activity was determined byusing the Dual-Luciferase® Reporter Assay System (Promega).

Sprouting Assay

For making collagen gels, an ice-cold solution of porcine type Icollagen (Nitta gelatin, Tokyo, Japan) was mixed with 10xRPMI1640 mediumand neutralization buffer at the ratio of 8:1:1. 400 μl aliquots ofcollagen gel were then added to 24-well plates and allowed to gel for atleast 1 hour at 37° C. Following adenoviral infection (above), HUVEC washarvested and plated at 1.3×10⁵ cells per well onto the top of thecollagen gel in 24-well plates in 0.8 ml of EGM2 medium. HUVEC becamenearly confluent 48 hours after plating. After seeding, medium waschanged every 2 days for 1 week. Sprouting was observed and photographstaken after 8 days with an Olympus digital camera mounted to amicroscope. For quantification of the number of sprouts, 5 fields pereach well were randomly selected and sprouting was counted undermicroscopy in a blind manner by two investigators.

Results and Discussion NOTCHECD/Fc Fusion Proteins Function asAntagonists of Notch Notch Antagonists-NotchECD/Fc Fusion Proteins

We have made several Notch antagonists (FIG. 2). Our strategy was tofuse the coding sequence of Notch EGF repeats in the ExtracellularDomain (ECD) to the human or mouse Fc domain. This design makes asecreted protein without signaling function but which retains theligand-binding domain and thus should bind to and inhibit ligandfunction. We refer to these proteins as “NotchECD/Fc” and all fourNotch1-4ECD/Fcs have been made. The Fc domain facilitates affinitypurification and protein detection by immunoblotting orimmunohistochemistry.

Testing Notch Antagonists

An in vitro co-culture system (FIG. 3) with ligands expressed on onecell and Notch receptor activation scored in another cell was used tomeasure transcriptional activation of the Notch pathway. We used thisco-culture assay to show that Notch1ECD/Fc functions to blockligand-dependent Notch signaling (FIG. 4). The N1ECD/Fc expressionvector was co-transfected at different ratios with full-length Notch1and the CSL-luciferase reporter in HeLa cells, followed by co-culturewith ligand expressing 293 cells. We observed that activation of Notch1signaling by Notch ligands was reduced by N1ECD/Fc expression. Thiseffect displayed concentration-dependency; a 2:1 ratio of N1ECD/Fc toNotch1 was more effective in inhibiting signaling than a 1:1 ratio.Notch1ECD/Fc could block signaling mediated by Jagged1, Delta-like 1 orDelta-like 4.

Expressing and Purifying Notch Antagonists

We have made CHO and HeLa cell lines expressing NotchECD/FCs usingretroviral vectors for the purpose of protein purification. N1ECD/Fcproteins are secreted (FIG. 5); as shown in conditioned media collectedfrom HeLa-NotchECD/Fc lines and purified with Protein-A(pA) agarose. ThepA purified sample (Sup) and whole cell lysates (Lys) were immunoblottedwith α-Fc antibody (FIG. 5, panel A) demonstrating that N1ECD/Fc issecreted into the media. Adenovirus vectors for NotchECD/Fc were used toinfect HeLa cells and lysates from these cells were immunoblotted withα-Fc antibodies demonstrating that they express NotchECD/Fc(1, 2, 3, 4)proteins (FIG. 5, panel B). We are currently purifying N1ECD/Fc from CHOcell conditioned media using pA-affinity chromatography.

Defining Angiogenic Inhibition Using Notch Fusion Proteins Activation ofNotch Signaling can be Detected by Using CBF1 Promoter Activity

One can measure Notch signaling function by measuring transcriptionalactivity of CBF1 promoter, which is activated by binding of Notch-IC toCBF1. We measured CBF1 promoter activity in HUVEC which was infectedwith adenovirus encoding VEGF-165 at different MOI (FIG. 6). Inductionof CBF1 promoter was clearly detected in Ad-VEGF-infected HUVEC,compared to Ad-LacZ-infected cells in the MOI dependent manner. Thisdata showed over-expression of VEGF could activate Notch signaling inHUVEC. Thus VEGF induced Notch signaling activity.

We asked whether Notch fusion proteins could block VEGF-inducedactivation of Notch signaling. Co-infection of Ad-Notch fusion proteinwith Ad-VEGF clearly reduced activation of CBF1 promoter activityinduced by Ad-VEGF infection alone (FIG. 7). In the case of infection at40 MOI for each adenovirus in FIG. 7 (panel A), 60% inhibition at 24 hrand 90% inhibition at 48 hr after reporter gene transfection weredetected also the inhibitory activity of Notch decoy was dependent onMOI of Ad-Notch fusion protein.

Notch Fusion Proteins Block Initiation of Angiogenic Sprouting Inducedby VEGF

In this experiment, we evaluated the effect of Notch decoy on inductionof budding (initiation of sprouting) by over-expressed VEGF-165 inHUVEC. When Ad-VEGF-infected HUVEC were cultured on type collagen gelfor 8 days, budding was induced into collagen gel. This induction ofbudding by overexpressed VEGF was clearly inhibited by coinfection ofadenoviral encoding Notch fusion protein (FIG. 8). Ad-Notch fusionprotein itself had less effect on morphology.

In FIG. 9 we counted buds per field using the microscope.Ad-VEGF-infection into HUVEC increased the number of buds depending onthe MOI used. Ad-VEGF-induced budding was clearly inhibited. These datasuggest that VEGF induced budding of HUVEC through activation of Notchsignaling and that the Notch fusion protein could inhibit VEGF-inducedbudding.

REFERENCES CITED IN SECOND SERIES OF EXPERIMENTS

-   1. Artavanis-Tsakonas, S., K. Matsuno, and M. E. Fortini. 1995.    Notch signaling. Science 268:225-232.-   2. Bailey, A. M., and J. W. Posakony. 1995. Suppressor of hairless    directly activates transcription of enhancer of split complex genes    in response to Notch receptor activity. Genes & Development    9:2609-22.-   3. Bettenhausen, B., M. Hrabe de Angelis, D. Simon, J. L. Guenet,    and A. Gossler. 1995. Transient and restricted expression during    mouse embryogenesis of Dll, a murine gene closely related to    Drosophila Delta. Development 121:2407-18.-   4. Blaumueller, C. M., H. Qi, P. Zagouras, and S.    Artavanis-Tsakonas. 1997. Intracellular cleavage of Notch leads to a    heterodimeric receptor on the plasma membrane. Cell 90:281-91.-   5. Caronti, B., L. Calandriello, A. Francia, L. Scorretti, M.    Manfredi, T. Sansolini, E. M. Pennisi, C. Calderaro, and G.    Palladini. 1998. Cerebral autosomal dominant arteriopathy with    subcortical infarcts and leucoencephalopathy (CADASIL).    Neuropathological and in vitro studies of abnormal elastogenesis.    Acta Neurol Scand. 98:259-67.-   6. Desmond, D. W., J. T. Moroney, T. Lynch, S. Chan, S. S.    Chin, D. C. Shungu, A. B. Naini, and J. P. Mohr. 1998. CADASIL in a    North American family: clinical, pathologic, and radiologic findings    [see comments]. Neurology 51:844-9.-   7. Dunwoodie, S. L., D. Henrique, S. M. Harrison, and R. S.    Beddington. 1997. Mouse D113: a novel divergent Delta gene which may    complement the function of other Delta homologues during early    pattern formation in the mouse embryo. Development 124:3065-76.-   8. Eastman, D. S., R. Slee, E. Skoufos, L. Bangalore, S. Bray,    and C. Delidakis. 1997. Synergy between suppressor of Hairless and    Notch in regulation of Enhancer of split in gamma and m delta    expression. Mol Cell Biol. 17:5620-5634.-   9. Fortini, M. E., and S. Artavanis-Tsakonas. 1993. Notch:    neurogenesis is only part of the picture. Cell 75:1245-7.-   10. Gale, N. W., and G. D. Yancopoulos. 1999. Growth factors acting    via endothelial cell-specific receptor tyrosine kinases: VEGFs,    Angiopoietins, and ephrins in vascular development. Genes and    Development 13:1055-1066.-   11. Gallahan, D., and R. Callahan. 1997. The mouse mammary tumor    associated gene INT3 is a unique member of the NOTCH gene family    (NOTCH4). Oncogene 14:1883-90.-   12. Greenwald, I. 1994. Structure/function studies of lin-12/Notch    proteins. Current Opinion in Genetics & Development 4:556-62.-   13. Greenwald, I. 1998. LIN-12/Notch signaling: lessons from worms    and flies. Genes Dev. 12:1751-62.-   14. Henderson, A. M., S. J. Wang, A. C. Taylor, M. Aitkenhead,    and C. C. W. Hughes. 2001. The basic helix-loop-helix transcription    factor HESR1 regulates endothelial cell tube formation. J Biol Chem.    276:6169-6176.-   15. Hicks, C., S. H. Johnston, G. diSibio, A. Collazo, T. F. Vogt,    and G. Weinmaster. 2000. Fringe differentially modulates Jagged1 and    Delta1 signalling through Notch1 and Notch2. Nature Cell Biology    2:515-520.-   16. Hsieh, J. J., T. Henkel, P. Salmon, E. Robey, M. G. Peterson,    and S. D. Hayward. 1996. Truncated mammalian Notch1 activates    CBF1/RBPJk-repressed genes by a mechanism resembling that of    Epstein-Barr virus EBNA2. Molecular & Cellular Biology 16:952-9.-   17. Hsieh, J. J., D. E. Nofziger, G. Weinmaster, and S. D.    Hayward. 1997. Epstein-Barr virus immortalization: Notch2 interacts    with CBF1 and blocks differentiation. J. Virol. 71:1938-45.-   18. Jarriault, S., C. Brou, F. Logeat, E. H. Schroeter, R. Kopan,    and A. Israel. 1995. Signaling downstream of activated mammalian    Notch. Nature 377:355-358.-   19. Joutel, A., F. Andreux, S. Gaulis, V. Domenga, M. Cecillon, N.    Battail, N. Piga, F. Chapon, C. Godfrain, and E.    Tournier-Lasserve. 2000. The ectodomain of the Notch3 receptor    accumulates within the cerebrovasculature of CADASIL patients [see    comments]. J Clin Invest. 105:597-605.-   20. Joutel, A., C. Corpechot, A. Ducros, K. Vahedi, H. Chabriat, P.    Mouton, S. Alamowitch, V. Domenga, M. Cecillion, E. Marechal, J.    Maciazek, C. Vayssiere, C. Cruaud, E. A. Cabanis, M. M. Ruchoux, J.    Weissenbach, J. F. Bach, M. G. Bousser, and E.    Tournier-Lasserve. 1996. Notch3 mutations in CADASIL, a hereditary    adult-onset condition causing stroke and dementia. Nature    383:707-10.-   21. Kopan, R., E. H. Schroeter, H. Weintraub, and J. S. Nye. 1996.    Signal transduction by activated mNotch: importance of proteolytic    processing and its regulation by the extracellular domain. Proc Natl    Acad Sci USA 93:1683-8.-   22. Krebs, L. T., Y. Xue, C. R. Norton, J. R. Shutter, M.    Maguire, J. P. Sundberg, D. Gallahan, V. Closson, J. Kitajewski, R.    Callahan, G. H. Smith, K. L. Stark, and T. Gridley. 2000. Notch    signaling is essential for vascular morphogenesis in mice. Genes and    Development 14:1343-1352.-   23. Lardelli, M., J. Dahlstrand, and U. Lendahl. 1994. The novel    Notch homologue mouse Notch3 lacks specific epidermal growth    factor-repeats and is expressed in proliferating neuroepithelium.    Mechanism of Development 46:123-136.-   24. Lawson, N. D., N. Scheer, V. N. Pham, C. Kim, A. B.    Chitnis, J. A. Campos-Ortega, and B. M. Weinstein. 2001. Notch    signaling is required for arterial-venous differentiation during    embryonic vascular development. Development 128:3675-3683.-   25. Lewis, J. 1998. Notch signaling and the control of cell fate    choices in vertebrates. Semin Cell Dev Biol. 9:583-589.-   26. Lieber, T., S. Kidd, E. Alcomo, V. Corbin, and M. W.    Young. 1993. Antineurogenic phenotypes induced by truncated Notch    proteins indicate a role in signal transduction and may point to a    novel function for Notch in nuclei. Genes Dev. 7:1949-1965.-   27. Lindner, V., C. Booth, I. Prudovsky, D. Small, T. Maciag, and L.    Liaw. 2001. Members of the Jagged/Notch gene familites are expressed    in injured arteries and regulate cell phenotype via alteration in    cell matrix and cell-cell interations. Pathology 159:875-883.-   28. Lindsell, C. E., C. J. Shawber, J. Boulter, and G.    Weinmaster. 1995. Jagged: A mammalian ligand that activates Notch1.    Cell 80:909-917.-   29. Logeat, F., C. Bessia, C. Brou, O. LeBail, S. Jarriault, N. G.    Seidah, and A. Israel. 1998. The Notch1 receptor is cleaved    constitutively by a furin-like convertase. Proc Natl Acad Sci USA    95:8108-12.-   30. Lyman, D., and M. W. Young. 1993. Further evidence for function    of the Drosophila Notch protein as a transmembrane receptor. Proc    Natl Acad Sci USA 90:10395-10399.-   31. Matsuno, K., M. J. Go, X. Sun, D. S. Eastman, and S.    Artavanis-Tsakonas. 1997. Suppressor of Hairless-independent events    in Notch signaling imply novel pathway elements. Development    124:4265-4273.-   32. Nakagawa, O., D. G. McFadden, M. Nakagawa, H. Yanagisawa, T.    Hu, D. Srivastava, and E. N. Olson. 2000. Members of the HRT family    of basic helix-loop-helix proteins act as transcriptional repressors    downstream of Notch signaling. Proc Natl Acad Sci USA    97:13655-13660.-   33. Oberg, C., J. Li, A. Pauley, E. Wolf, M. Gurney, and U.    Lendahl. 2001. The Notch intracellular domain is ubiquitinated and    negatively regulated by the mammalian Sel-10 homolog. J Biol Chem.    276:35847-35853.-   34. Owens, G. K. 1995. Regulation of differentiation of vascular    smooth muscle cells. Physiol Rev. 75:487-527.-   35. Rebay, I., R. G. Fehon, and S. Artavanis-Tsakonas. 1993.    Specific truncations of Drosophila Notch define dominant activated    and dominant negative forms of the receptor. Cell 74:319-29.-   36. Robey, E. 1997. Notch in vertebrates. Curr Opin Genet Dev.    7:551-7.-   37. Roehl, H., M. Bosenberg, R. Blelloch, and J. Kimble. 1996. Roles    of the RAM and ANK domains in signaling by the C. elegans GLP-1    receptor. Embo J. 15:7002-7012.-   38. Rogers, S., R. Wells, and M. Rechsteiner. 1986. Amino acid    sequences common to rapidly degrade proteins: The PEST hypothesis.    Science 234:364-368.-   39. Sasai, Y., R. Kageyama, Y. Tagawa, R. Shigemoto, and S.    Nakanishi. 1992. Two mammalian helix-loop-helix factors structurally    related to Drosophila hairy and Enhancer of split. Genes & Dev.    6:2620-2634.-   40. Shawber, C., J. Boulter, C. E. Lindsell, and G. Weinmaster.    1996a. Jagged2: a serrate-like gene expressed during rat    embryogenesis. Dev Biol. 180:370-6.-   41. Shawber, C., D. Nofziger, J. J. Hsieh, C. Lindsell, O.    Bogler, D. Hayward, and G. Weinmaster. 1996b. Notch signaling    inhibits muscle cell differentiation through a CBF1-independent    pathway. Development 122:3765-73.-   42. Shimizu, K., S. Chiba, T. Saito, T. Takahashi, K. Kumano, H.    Hamada, and H. Hirai. 2002. Integrity of intracellular domain of    Notch ligand is indespensable for cleavage required for the release    of the Notch2 intracellular domain. Embo J. 21:294-302.-   43. Shutter, J. R., S. Scully, W. Fan, W. G. Richards, J.    Kitajewski, G. A. Deblandre, C. R. Kintner, and K. L. Stark. 2000a.    Dll4, a novel Notch ligand expressed in arterial endothelium. Genes    Dev. 14:1313-1318.-   44. Shutter, J. R., S. Scully, W. Fan, W. G. Richards, J.    Kitajewski, G. A. Deblandre, C. R. Kitner, and K. L. Stark. 2000b.    Dll4, a novel Notch ligand expressed in arterial endothelium. Genes    and Development 14:1313-1318.-   45. Struhi, G., K. Fitzgerald, and I. Greenwald. 1993. Intrinsic    activity of the Lin-12 and Notch intracellular domains in vivo. Cell    74:331-45.-   46. Swiatek, P. J., C. E. Lindsell, F. Franco del Amo, G.    Weinmaster, and T. Gridley. 1994. Notch 1 is essential for    postimplantation development in mice. Genes & Development 8:707-719.-   47. Tamura, K., Y. Taniguchi, S. Minoguchi, T. Sakai, T. Tun, T.    Furukawa, and T. Honjo. 1995. Physical interaction between a novel    domain of the receptor Notch and the transcription factor RBP-J    kappa/Su(H). Curr Biol. 5:1416-1423.-   48. Tietze, K., N. Oellers, and E. Knust. 1992. Enhancer of splitD,    a dominant mutation of Drosophila, and its use in the study of    functional domains of a helix-loop-helix protein. Proc Natl Acad Sci    USA 89:6152-6156.-   49. Uyttendaele, H., J. Ho, J. Rossant, and J. Kitajewski. 2001.    Vascular patterning defects associated with expression of activated    Notch4 in embryonic endothelium. PNAS. 98:5643-5648.-   50. Uyttendaele, H., G. Marazzi, G. Wu, Q. Yan, D. Sassoon, and J.    Kitajewski. 1996. Notch4/int-3, a mammary proto-oncogene, is an    endothelial cell-specific mammalian Notch gene. Development    122:2251-9.-   51. Vervoort, M., C. Dambly-Chaudiere, and A. Ghysen. 1997. Cell    fate determination in Drosophila. Curr Opin Neurobiol. 7:21-28.-   52. Villa, N., L. Walker, C. E. Lindsell, J. Gasson, M. L.    Iruela-Arispe, and G. Weinmaster. 2001. Vascular expression of Notch    pathway receptors and ligands is restricted to arterial vessels.    Mechanisms of Development 108:161-164.-   53. Weinmaster, G. 1997. The Ins and Outs of Notch Signaling. Mol    Cel Neurosci. 9:91-102.-   54. Weinmaster, G. 1998. Notch signaling: direct or what? Curr Opin    Genet Dev. 8:436-42.-   55. Weinmaster, G., V. J. Roberts, and G. Lemke. 1992. Notch 2: a    second mammalian Notch gene. Development 116:931-941.-   56. Weinmaster, G., V. J. Roberts, and G. A. Lemke. 1991. A homolog    of Drosophila Notch expressed during mammalian development.    Development 113:199-205.-   57. Wettstein, D. A., D. L. Turner, and C. Kintner. 1997. The    Xenopus homolog of Drosophila Suppressor of Hairless mediates Notch    signaling during primary neurogenesis. Development 124:693-702.-   58. Wu, G., E. J. Hubbard, J. K. Kitajewski, and I. Greenwald. 1998.    Evidence for functional and physical association between    Caenorhabditis elegans SEL-10, a Cdc4p-related protein, and SEL-12    presenilin. Proc Natl Aced Sci USA 95:15787-91.-   59. Wu, G., S. A. Lyapina, I. Das, J. Li, M. Gurney, A. Pauley, I.    Chui, R. J. Deshaies, and J. Kitajewski. 2001. SEL-10 is an    inhibitor of notch signaling that targets notch for    ubiquitin-mediated protein degradation. Mol Cell Biol. 21:7403-7015.-   60. Xue, Y., X. Gao, C. E. Lindsell, C. R. Norton, B. Chang, C.    Hicks, M. Gendron-Maguire, E. B. Rand, G. Weinmaster, and T.    Gridley. 1999. Embryonic lethality and vascular defects in mice    lacking the Notch ligand Jagged1. Hum Mol Genet. 8:723-30.

Third Series of Experiments VEGF Initiates Angiogenesis Via anActivation of Notch Signaling

Both the VEGF and Notch signaling pathways are critical for vasculardevelopment. Here we show that VEGF activates Notch signaling toinitiate angiogenesis. VEGF increased the expression of Delta4 andNotch4 causing Notch signal activation and inducing filopodia incultured primary endothelial cells. Studies using VEGF Receptorinhibitors show that Notch signal activation in turn enhances VEGFaction by inducing VEGFR-1 (Flt-1) expression. Other elements of VEGFaction, including the induction of MMP-9 and MT1-MMP, are mediated byNotch. Using in vivo assays to model VEGF-induced skinneovascularization, we found that a secreted Notch inhibitor(Notch-based fusion protein) blocks VEGF-induced neo-vascularization andinduction of VEGFR-1 expression. Thus, Notch signaling is requisite forangiogenesis regulated by VEGF, likely at the level of initiation.

VEGF is a key regulator of angiogenesis progression consisting ofmultiple processes, such as degradation of ECM, budding (filopodiaformation), proliferation, survival, and migration of endothelial cells.Although most of the steps might be co-operated with downstreammolecules of VEGF signaling, it is not known how these steps arecoordinately regulated to result in more complex morphogenetic events,such as angiogenic sprouting. Notch signaling is an evolutionarilyconserved signaling mechanism that functions to regulate cell fatedecisions (1). Upon binding by a ligand, such as Jagged and Delta-like,the cytoplasmic domain of Notch (NotchIC) is released bypresenilin/y-secretase, translocates to the nucleus, interacts with thetranscriptional repressor CSL (CBF1/Su(H)/lag2), and converts it to atranscriptional activator (1). Roles of Notch signaling in vasculardevelopment were suggested by studies of mice with targeted mutation(2). Since Notch activation within the endothelium also disruptsvascular remodeling, proper Notch signaling is essential for vasculardevelopment (3). Although relevance of Notch to VEGF signaling issuggested (4-6), it is still unclear how Notch signaling has a role inVEGF-regulated angiogenesis and whether Notch signaling participates inphysiological and pathological angiogenesis in the adult vasculature.

HUVEC (Human Umbilical Vein Endothelial cells) growth are dependent onVEGF (FIGS. 26A and 26B) and differentiation-related biologicalresponses, such as sprouting, and can be evaluated at an early stage(7). At first, we examined whether adenovirally transduced VEGF inducedboth Notch and Notch ligand expression in HUVEC cultured with completemedium containing bFGF (FIG. 22A), as reported (5). RT-PCR analysisshowed that both Dl4 and Notch4 mRNA was up-regulated inadenovirally-transduced VEGF HUVEC (Ad-VEGF-HUVEC), compared toadenovirally-transduced LacZ HUVEC (Ad-LacZ-HUVEC) (FIG. 22A).Transduced VEGF did not appear to induce Jagged1 and Notch1 expression.Transduced-VEGF also activated Notch signaling in a dose-dependentmanner by measuring CSL-luciferase reporter activity (FIG. 22B), whichwas transactivated with Notch signaling (8). Notch signaling wasactivated at a higher dosage of Ad-VEGF, compared to proliferation (FIG.26A). Since SU5416, which is an inhibitor of VEGFR kinases, decreasedVEGF-induced CSL-luciferase reporter activity (FIG. 22C), VEGF inducedNotch signaling through activation of receptor kinase. Since Notchmutants lacking both transmembrane and cytoplasmic domains functioned asdominant negative inhibitors against Notch signaling (9), we made aNotch-based fusion protein or decoy (N1ECDFc) to inhibit Notch signaling(FIG. 22D). Western blotting analysis of conditioned medium ofAd-N1ECDFc-transduced HUVEC (Ad-N1ECDFc-HUVEC) demonstrated that N1ECDFcwas expressed and secreted well (FIG. 22E). By using a co-culture assay,in which Bosc cells expressing Notch ligands (either J1, Dll or Dl4)activated Notch signaling in HeLa cells expressing Notch1 compared tocontrol Bosc cells, we determined inhibition of Notch signaling withtransfection of a N1ECDFc-expression plasmid (FIG. 22F). Then, weexamined whether N1ECDFc inhibited activation of Notch signaling bytransduced VEGF in HUVEC (FIG. 22G). Co-transduction of Ad-N1ECDFc withAd-VEGF into HUVEC clearly decreased CSL luciferase activity induced byVEGF. Gerhardt et al. reported that VEGF controlled angiogenesis in theearly postnatal retina by guiding filopodia extension at the tips of thevascular sprouts (10). During angiogenic sprouting, the formation of aspecialized endothelial cell making filopodia projections amongquiescent endothelial cells, might be one of the early events. Here wemean formation of a single endothelial cell making filopodia protrusionsas budding. Budding of the primary endothelial cells is induced bycultivating them 3-dimensionally on either fibrin or collagen gel (11).In the case where Ad-VEGF-HUVEC were cultured on collagen gel withcomplete medium, transduced-HUVEC made filopodia extensions into thecollagen gel for 5 days (FIG. 22H) and the number of buds was increasedin a dose-dependent manner (FIG. 27A). Activation of Notch signaling byadenovirus encoding the activated form of Notch4 (Ad-Notch4/int3)induced HUVEC budding (12) and that of Notch1 (Ad-N1IC) also inducedHUVEC budding (FIGS. 23A & 27B). Since both VEGF and Notch signalinginduce HUVEC budding, we examined whether N1ECDFc inhibited VEGF-inducedHUVEC budding (FIG. 22H-I). Budding of Ad-VEGF-HUVEC was clearlyinhibited by co-transduction of Ad-N1ECDFc. Neither Ad-LacZ orAd-N1ECDFc-transduced HUVEC formed buds (FIG. 22H). N1ECDFc inhibitedVEGF-induced HUVEC budding without affecting cell number (FIG. 22I).Transduced-N1ECDFc did not clearly alter proliferation of HUVEC, whilethat of Ad-N1IC-transduced HUVEC was inhibited in a dose-dependentmanner (FIG. 28A), consistent with the inhibitory efficacy of Notchsignaling against endothelial proliferation (13).

To test whether Notch signaling is down-stream of VEGF, we evaluatedthree distinct inhibitors for receptor tyrosine kinases, including VEGFRon N1IC-induced HUVEC budding, because three growth factors existed incomplete medium (FIG. 23A-C). At a concentration of 1 μM, each compoundshowed selective inhibition against each kinase (data not shown).Neither P13166866 or ZD1893 affected budding of Ad-N1IC-HUVEC, whileSU5416 clearly inhibited it (FIG. 23A-B). SU5416 selectively inhibitedbudding of Ad-N1IC-HUVEC with less reduction of viability at lowerconcentrations (FIG. 23C). Since Taylor et al. reported that Notchdown-regulated Flk1/KDR/VEGFR2 expression (14), it was unlikely thatNotch co-operated with Flk1 to promote budding. Thus, we examinedwhether activation of Notch signaling affected Flt1/VEGFR1 expression inHUVEC, because SU5416 inhibits both Flt1 and Flk1 kinase activity (15).RT-PCR analysis demonstrated that expression of Flt1 mRNA wasup-regulated in Ad-N1IC-HUVEC, while expression of endothelial cellmaker, CD31 mRNA, was not compared to that in Ad-LacZ-HUVEC (FIG. 23D).western blotting analysis also showed that expression of Flt1 proteinwas up-regulated in Ad-N1IC-HUVEC (FIG. 23E). Thus, we examined whetherP1GF, which is a selective ligand for Flt1, promoted budding of HUVEC inwhich Flt1 was up-regulated via activation of Notch signaling (FIG.23F-G). P1GF increased the number of Ad-N1IC-HUVEC buds by 150%,compared to the absence of P1GF (FIG. 23F). Moreover, P1GF increasedHUVEC buds containing multiple filopodia by 250% (FIG. 23G). Whilereduction of Flt1 expression using small interfering RNA (siRNA) forFlt1 inhibited budding of Ad-N1IC-HUVEC (FIG. 23J), transfection ofwhich selectively decreased expression of Flt1 mRNA (FIG. 23H) and thatof Flt1 protein (FIG. 23I). Although reduction of Flk1 expression withFlk1 siRNA also inhibited budding of Ad-N1IC-HUVEC (FIG. 30B), theinhibitory efficacy of Flk1 siRNA was less than that of Flt1 siRNA (FIG.23J). Effects of Flk1 siRNA were more effective on budding ofAd-VEGF-HUVEC than that of Ad-N1IC-HUVEC (FIG. 30B-C). Transfection withFlt1 siRNA inhibited budding of both Ad-N1IC- and Ad-VEGF-HUVEC to asimilar extent (data not shown).

Several studies demonstrated that VEGF regulated gelatinase activitiesin endothelial cells and the significance of gelatinase activity likeMMP-2 and MMP-9 has been firmly established to induce angiogenicsprouting (16). We examined whether VEGF regulated gelatinase activityvia Notch signaling in HUVEC.

In Gelatin zymography, conditioned medium of Ad-VEGF-HUVEC showed bothinduction and activation of MMP9, which started to be detected at day 6(FIG. 24A) and activation of MMP2, which was detected at day 4 (FIG.24B), compared to those of Ad-LacZ-HUVEC. Co-transduction of Ad-N1ECDFcwith Ad-VEGF showed inhibition of both induction and activation of MMP9(FIG. 24A) and an activation of MMP2 (FIG. 24B). RT-PCR analysisdemonstrated that expression of MMP9 mRNA was up-regulated inAd-N1IC-HUVEC, but expression of MMP2 mRNA was decreased inAd-N1IC-HUVEC (FIG. 24C). Since induction of MMP2 activity was notdetected in gelatin zymography (FIG. 24B), this result was a likelyconsequence. While expression of MT1-MMP, which is able to activate MMP2at the cell surface (17), was up-regulated at both the transcript andprotein levels in Ad-N1IC-HUVEC (FIG. 24D). As VEGF can regulate bothgelatinase and MT1-MMP expression (16), RT-PCR analysis demonstratedthat both MMP9 and MT1-MMP were up-regulated in Ad-VEGF-HUVEC, comparedto Ad-LacZ-HUVEC and this induction was inhibited with co-transductionof Ad-N1ECDFc (FIG. 24E). Ad-N1ECDFc infection alone did not affectexpression of either MMP9 or MT1-MMP in Ad-LacZ infected HUVEC (data notshown). Requisition of MMPs for angiogenic sprouting has beenestablished by synthetic MMP inhibitors (16). GM6001 is one broadinhibitor against MMPs including MMP2, MMP9 and MT1-MMP (18). GM6001clearly decreased budding of Ad-N1IC-HUVEC on both collagen (FIG. 31A-B)and fibrin gel (data not shown).

In the mouse Dorsa Air Sac (DAS) assay (19), stable transfectant of 293cells over-expressing VEGF121 (293/VEGF) significantly induced in vivoangiogenesis (FIG. 25A, left panel). This VEGF-induced angiogenesis wasclearly inhibited by coexpression of N1ECDFc, compared to 293/VEGF alone(FIG. 25A). Vessel density was measured and an index of angiogenesisgiven in FIG. 25B, demonstrating the 293/VEGF induced angiogenesis isinhibited by co-expression of 293/N1ECDFc (FIG. 25B).

Also, in the mouse Dorsa Air Sac (DAS) assay (19), the human breastcancer cell line, MDA-MB-231 significantly induced in vivo angiogenesis,presumably via the secretion of VEGF (FIG. 25C, left panel). ThisVEGF-induced angiogenesis was clearly inhibited by adenovirus mediatedexpression of N1ECDFc, compared to adenovirus expressing LacZ. (FIG.25C). Vessel density was measured and an index of angiogenesis given inFIG. 25D, demonstrating the MDA-MB-231 induced angiogenesis is inhibitedby expression of N1ECDFc. Flk1 is a major positive signal transducer forangiogenesis through its strong tyrosine kinase activity in the embryo,while Flt1 is thought to be a negative signal transducer forangiogenesis. However, a positive role for Flt-1 was demonstrated inadult mice, as in vivo growth of LLC over-expressing P1GF2 was severelycompromised in mice lacking the cytoplasmic Flt-1 kinase domain (20).Notch might function to alter VEGF signaling by inducing Flt-1 signalingand moderate Flk-1 signaling either to induce filopodia extension orpotentiate angiogenic sprouting, since P1GF/Flt-1 signaling altered thephospholyration site of Flk-1 and potentiated ischemic myocardialangiogenesis (21). Interestingly, Notch signaling also up-regulated P1GFexpression (FIG. 29). However, continuous activation of Notch signalinginhibits formation of multi-cellular lumen-containing angiogenicsprouts, as previously reported (22). Notch signaling should be turnedoff after budding/filopodia formation and transient activation of theNotch pathway might be required. In a transgenic mouse model ofpancreatic beta-cell carcinogenesis (Rip1Tag2 mice) in which tumorangiogenesis is VEGF dependent, the level of VEGF expression is notincreased, but mobilization of extracellular VEGF stored in the matrixto VEGF receptors occurs. MMP-9 is responsible for this mobilization andtumor progression was inhibited in Rip1Tag23MMP-9-null double-transgenicmice (23). Notch up-regulated MMP-9 expression and might increase localVEGF level at the site for angiogenic sprouting. While Notch alsoup-regulates MT1-MMP expression, extracellular MMP-2 might be targetedto the cell membrane of Notch-activated endothelial cells. Notch mightdetermine the site for angiogenic sprouting by regulating gelatinaseactivity and VEGF concentration. Since endothelial MMP-9 was regulatedby Flt-1 in lung specific metastasis (20), Flt-1 might participate ininduction of MMP-9 indirectly.

REFERENCES CITED IN THIRD SERIES OF EXPERIMENTS

-   1. Artavanis-Tsakonas 5, Rand M D, Lake R J. Notch Signaling: Cell    Fate Control and Signal Integration in Development. Science 1999;    284(5415):770-776.-   2. Shawber C J, J. K. Notch function in the vasculature: insights    from zebrafish, mouse and man. Bioessays. 2004; 26(3):225-34.-   3. Uyttendaele H, Ho J, Rossant J, J. K. Vascular patterning defects    associated with expression of activated Notch4 in embryonic    endothelium. Proc Natl Acad Sci USA. 2001; 98(10):5643-8.-   4. Lawson N D, Vogel A M, BM. W. sonic hedgehog and vascular    endothelial growth factor act upstream of the Notch pathway during    arterial endothelial differentiation. Dev Cell 2002; 3(1):127-36.-   5. Liu Z J, Shirakawa T, Li Y, Soma A, Oka M, Dotto G P, et al.    Regulation of Notch1 and Dll4 by vascular endothelial growth factor    in arterial endothelial cells: implications for modulating    arteriogenesis and angiogenesis. Mol Cell Biol. 2003; 23(1):14-25.-   6. Gale N W, Dominguez M G, Noguera I, Pan L, Hughes V, Valenzuela D    M, et al. Haploinsufficiency of delta-like 4 ligand results in    embryonic lethality due to major defects in arterial and vascular    development. Proc Natl Acad Sci USA. 2004; 101(45):5949-54.-   7. Montesano R, L. O. Phorbol esters induce angiogenesis in vitro    from large-vessel endothelial cells. J Cell Physiol. 1987;    130(2):284-91.-   8. Jarriault S. Brou C, Logeat F, Schroeter E H, Kopan R, A. I.    Signalling downstream of activated mammalian Notch. Nature. 1995;    377(6547):355-8.-   9. Small D, Kovalenko D, Kacer D, Liaw L, Landriscina M, Di Serio C,    et al. Soluble Jagged 1 represses the function of its transmembrane    form to induce the formation of the Src-dependent chord-like    phenotype. J Biol Chem 2001; 276(34):32022-30.-   10. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A,    Abramsson A, et al. VEGF guides angiogenic sprouting utilizing    endothelial tip cell filopodia. J Cell Biol 2003; 161(6):1163-77.-   11. Koolwijk P, van Erck M G, de Vree W J, Vermeer M A, Weich H A,    Hanemaaijer R, et al. Cooperative effect of TNFalpha, bFGF, and VEGF    on the formation of tubular structures of human microvascular    endothelial cells in a fibrin matrix. Role of urokinase activity. J    Cell Biol 1996; 132(6):1177-88.-   12. Das I, Craig C, Funahashi Y, Jung K M, Kim T W, Byers R, et al.    Notch oncoproteins depend on gamma-secretase/presenilin activity for    processing and function. J Biol Chem 2004; 279(29):30771-80.-   13. Noseda M, Chang L, McLean G, Grim J E, Clurman B E, Smith L L,    et al. Notch activation induces endothelial cell cycle arrest and    participates in contact inhibition: role of p21Cip1 repression. Mol    Cell Biol 200424(20):8813-22.-   14. Taylor K L, Henderson A M, CC. H. Notch activation during    endothelial cell network formation in vitro targets the basic HLH    transcription factor HESR-1 and downregulates VEGFR-2/KDR    expression. Microvasc Res 2002; 64(3):372-83.-   15. Itokawa T, Nokihara H, Nishioka Y, Sone S. Iwamoto Y, Yamada Y,    et al. Antiangiogenic effect by SU5416 is partly attributable to    inhibition of Flt-1 receptor signaling. Mol Cancer Ther 2002;    1(5):295-302.-   16. Pepper M S. Role of the matrix metalloproteinase and plasminogen    activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc    Biol 2001; 21(7):1104-17.-   17. Seiki M, Koshikawa N, I. Y. Role of pericellular proteolysis by    membrane-type 1 matrix metalloproteinase in cancer invasion and    angiogenesis. Cancer Metastasis Rev 2003; 22(2-3):129-43.-   18. Yamamoto M, Tsujishita H, Hori N, Ohishi Y, Inoue S, Ikeda S, et    al. Inhibition of membrane-type 1 matrix metalloproteinase by    hydroxamate inhibitors: an examination of the subsite pocket. J Med    Chem 1998; 41(8):1209-17.-   19. Funahashi Y, Wakabayashi T, Samba T, Sonoda J, Kitoh K, K. Y.    Establishment of a quantitative mouse dorsal air sac model and its    application to evaluate a new angiogenesis inhibitor. Oncol Res.    1999; 11(7):319-29.-   20. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H,    et al. MMP9 induction by vascular endothelial growth factor    receptor-1 is involved in lung-specific metastasis. Cancer Cell    2002; 2(4):289-300.-   21. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L,    Lambrechts D, et al. Role of P1GF in the intra- and intermolecular    cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003;    9(7):936-43.-   22. Leong K G, Hu X L L, Noseda M, Larrivee B, Hull C, Hood L, et    al. Activated Notch4 inhibits angiogenesis: role of beta 1-integrin    activation. Mol Cell Biol 2002; 22(8):2830-41.-   23. Bergers G, Brekken R, McMahon G, Vu T H, Itoh T, Tamaki K, et    al. Matrix metalloproteinase-9 triggers the angiogenic switch during    carcinogenesis. Nat Cell Biol 2000; 2(10):737-44.

Fourth Series of Experiments Expression of Notch Proteins and Ligands inBlood and Lymphatic Endothelial Cells.

RT-PCR was performed for Notch1-4, Dll1, Dll4 and Jagged1 on RNAisolated from blood endothelial cells (BEC) and lymphatic endothelialcells (LEC) purified from HMVEC. As shown in in FIG. 44, Notch1, Notch2,Notch4, Dll4 and Jagged1 were expressed in both BEC and LEC at a similarlevel. Expression of Notch 3 appears to be restricted to the LECsuggestive of Notch3 signaling functions in the lymphatic endothelium.

Notch3 is Co-Expressed with the Lymphatic Endothelial Cell Marker LYVE-1and Prox1 in e13.5 Embryos.

10 micron serial sections of embryonic day 13.5 mouse embryos wereimmunostained for either LYVE-1, Prox1 and Notch3. As shown in FIG. 45,Notch3 was expressed in the cells that also expressed the lymphaticendothelial cell markers, LYVE-1 and Prox1.

Prox1 Induced Notch3 Expression in Blood Endothelial Cells.

It was examined if ectopic expression of Prox1 would alter theexpression of Notch proteins or ligands. As shown in FIG. 46, section A,twenty-four hours post adenoviral infection with either Ad-Prox1 orAd-LacZ, HUVEC total RNA was isolated and quantitative RT-PCR forNotch1-4, Dll4 and Jagged1 performed. Prox-1 robustly upregulated theexpression of Notch3. Notch1, Notch2, Notch4, Dll4 and Jagged1expression was not significantly affected. As shown in FIG. 46, sectionB, Compound E (cE), Presenlin inhibitor that inhibits Notch signaling,was incubated for 24 hours on either Ad-LacZ or Ad-Prox1 infected HUVEC.Total RNA was isolated and quantitative RT-PCR performed to determineNotch3 expression. Prox1 induced Notch3 expression and this inductionwas inhibited by the addition of compound E.

This suggests that the Prox1 induction of Notch3 is dependent on Notchsignal activation.

Prox1 Induces Notch-Target Genes in Blood Endothelial Cells.

HUVEC were infected with adenoviruses encoding, LacZ, Prox1, N1IC orN4/int-3 and total RNA isolated 24 hours post-infection. QuantitativeRT-PCR was performed for the endothelial Notch-target genes, VEGFR-3,EphrinB2, Hey1 and Hey2. Similar to Notch1 and Notch4 signal activation,Prox1 induced all four genes (FIG. 47, sections A and B). Expression ofHey1 and Hey2 in the lymphatic endothelium is unknown.

Prox1 Induces Notch-Target Genes is Dependent on Notch Signaling inBlood Endothelial Cells.

HUVEC were infected with adenoviruses encoding LacZ, Prox1, N1Ic orN4/int-3. Compound E(cE), Presenlin inhibitor that inhibits Notchsignaling, was incubated for 24 hours on either Ad-LacZ or Ad-Prox1infected HUVEC and total RNA isolated. Quantitative RT-PCR was performedfor the endothelial Notch-target genes, VEGFR-3, EphrinB2, and Hey2. TheProx-1 mediated induction of the Notch target genes, ephrinB2, VEGFR-3and Hey2 was inhibited by the addition of the Notch signaling inhibitorCompound E, as shown in FIG. 48. Thus, Prox1 regulates the expression ofephrinB2, VEGFR-3 and Hey2 via Notch.

Fifth Series of Experiments Background

Insights into a function for Notch in vascular homeostasis can be drawnfrom the human neurovascular disorder, Cerebral Autosomal DominantArteriopathy with Subcortical Infarcts and Leukoencephalopathy(CADASIL). In a majority of patients, CADASIL has been found tocorrelate with missense mutation in Notch3. CADASIL is a late-onset(average age of 45) autosomal dominant disorder characterized bymigraines with aura and recurrent strokes that lead to psychiatricsymptoms, progressive cognitive decline, dementia, and death⁽⁸¹⁾. Theseneuropathological symptoms arise secondary to a slow developingarteriopathy, associated with the disorganization and destruction of thevascular smooth muscle cells surrounding the cerebral arteries andarterioles. Regression of vascular smooth muscle cells is associatedwith a decrease in vessel wall thickness, a loss of extracellularmatrix, and vessel wall weakness⁽⁸²⁾. Within the vascular smooth musclecells, there is an accumulation of the extracellular domain of Notch3and in the extracellular matrix, an abnormal deposition of particlesreferred to as granular osmophilic materials (GOM)⁽⁸³⁾. In thisdisorder, arterial lesions are not restricted to the brain and are foundin arteries of the skin and retina⁽⁸³⁻⁸⁵⁾.

The CADASIL phenotype correlates with the expression of Notch3 invascular smooth muscle cells^((70,81)). The hypothesis being that Notch3functions to maintain cell-cell interactions or communication betweenvascular smooth muscle cells and arterial endothelial cells. A recentstudy has recreated the CADASIL vessel pathology in transgenic mice thatexpress a Notch3 transgene encoding the CADASIL R90C mutationspecifically in vascular smooth muscle cells⁽⁸⁶⁾. The vasculature ofthese mice showed classic CADASIL arteriopathy, including GOM depositsand Notch3 accumulation. However, these hallmarks were preceded by thedisruption of anchorage and adhesion of vascular smooth muscle cells toneighboring cells followed by degeneration of the vascular smooth musclecells. Thus, CADASIL, results from reduced vascular smooth muscle cellcontact and viability and the GOM deposition and accumulation of theextracellular domain of Notch3 are secondary consequences of thiscellular deterioration. Consistent with a role for Notch3 in cellsurvival, expression of a constitutively active form of Notch3 in rataortic smooth muscle cells resulted in the induction of cFlip, anantagonist of Fas-dependent apoptosis⁽⁸⁷⁾. In addition, ectopicexpression of Hey1 in cultured vascular smooth muscle cells promotedcell survival via Akt and thus inhibited apoptosis in response to serumstarvation and Fas ligand⁽⁸⁸⁾. Taken together, this data indicate thatNotch3 maintains arterial vessel homeostasis by promoting vascularsmooth muscle cell survival. The resulting arterial vessel wallleakiness could arise from vascular smooth muscle cell death or afailure of vascular smooth muscle cells to communicate to theirneighboring endothelial cells. Disruption of Notch3 activity in mice mayhelp define the nature of this defect.

The specific activity of CADASIL mutant Notch3 proteins is still poorlyunderstood. One complication in interpreting mutant Notch3 functionarises from conflicting in vitro studies that have shown that truncatedcytoplasmic Notch3 can either inhibit or activate the CSL transcriptionfactor^((89,90)).

Activation of Notch Signaling in Vascular Smooth Muscle Cells Results inEmbryonic Lethality.

Notch3 is expressed and active in cells that surround blood vessels, thesmooth muscle cells and pericytes. Smooth muscles cells are importantfor cardiovascular function and they must be healthy to prevent stroke.Pericytes can contribute to tumor vessel growth. Notch1 and Notch4 arenot though to function in these cells types.

Therefore the Notch3 fusion proteins described herein may be useful toprevent stroke by preventing abnormal Notch3 activity. In addition, theNotch3 fusion proteins may be useful to maintain vascular smooth musclecells, to restrain tumor pericyte growth or function, or to affectretinal angigogenesis by modulating pericyte function.

We have constructed a transgenic mouse that expresses an activated formof Notch1 (N1IC) under the control of the elongation factor 1-alphapromoter (EF1α) in tissues that express Cre-recombinase, referred to asEF1 α^(N1IC/+) (FIG. 49). EF1 α^(N1IC/+) is viable and fertile (FIG.50). We have expressed N1IC in vascular smooth muscle cells by crossingEF1 α^(N1IC/+) with an SM22-Cre mouse line (SM22^(cre/+)).

The resulting SM22^(Cre/+);EF1 α^(N1IC/+) double transgenic the at E9.5(FIG. 50). SM22^(cre/+);EF1 α^(N1IC/+) embryos display myocardialdefects that we believe are responsible for embryonic lethality.Consistent with these myocardial smooth muscle cells defects, weobserved an alteration in the expression of the vascular smooth musclecell marker, alpha smooth muscle cell actin in E9.5 SM22^(Cre/+);EF1α^(N1IC/+) transgenic animals (FIG. 51). These results demonstratingthat increased Notch signaling in vascular smooth muscle cells disruptsembryonic cardiovascular development.

REFERENCES CITED IN FIFTH SERIES OF EXPERIMENTS

-   81. Viitanen M, Kalimo H. CADASIL: Hereditary arteriopathy leading    to multiple brain infarcts and dementia. Ann. N.Y. Acad. Sci. 2000;    903:273-84.-   82. Brulin P. Godfraind C, Leteurtre E, Ruchoux M M. Morphometric    analysis of ultrastructural vascular changes in CADASIL: analysis of    50 skin biopsy specimens and pathogenic implications. Acta.    Neuropathol. 2002; 104:241-8.-   83. Uyama E, Tokunaga M, Suenaga A, Kotorii S, Kamimura K, Takahashi    K, Tabira T, Uchino M. Arg133Cys mutation of Notch3 in two unrelated    Japanese families with CADASIL. Intern. Med. 2000; 39(9):732-7.-   84, Joutel A, Favrole P. Labauge P, Chabriat H, Lescoat C, Andreux    F, Domenga V. Cecillon M, Vahedi K, Ducros A and others. Skin biospy    immunostaining with a Notch3 monoclonal antibody for CADASIL    diagnosis. Lancet 2001; 358:2049-51.-   85. Smith B W, Henneberry J, Connolly T. Skin biopsy findings in    CADASIL. Neurology 2002; 59(6):961.-   86. Ruchoux M M, Domenga V, Brulin P, Maciazek J, Limol S.    Tournier-Lasserve E, Joutel A. Transgenic mice expressing mutant    Notch3 develop vascular alterations characteristic of cerebral    autosomal dominant arteriopathy with subcortical infarcts and    leuckoencephalopathy. Am. J. Path. 2003; 162(1):329-42.-   87. Wang W, Prince C Z, Mou Y, Pollman M J. Notch3 signaling in    vascular smooth muscle cells induces c-FLIP expression via ERK/MAPK    activation. J Biol Chem 2002; 277(24):21723-9.-   88. Wang W, Prince C Z, Hu X, Pollman M J. HRT1 modulates vascular    smooth muscle cell proliferation and apoptosis. Biochem Biophys Res    Commun 2003; 308(3):596-601.-   89. Beatus P. Lundkvist J, Oberg C, Lendahl U. The Notch3    intracellular domain represses Notch1-mediated activation through    Hairy/Enhancer of split (HES) promoters. Development 1999;    126(17):3925-35.-   90. Saxena M T, Schroeter E H, Mumm J S, Kopan R. Murine notch    homologs (N1-4) undergo presenilin-dependent proteolysis. J. Biol.    Chem. 2001; 276(43):40268-73.

1. A fusion protein comprising a signal peptide, EGF repeats 1-X of theextracellular domain of human Notch3 receptor protein wherein X is anyinteger from 1-10 or 12 to 34, and an Fc portion of an antibody boundthereto.
 2. (canceled)
 3. (canceled)
 4. A fusion protein comprising asignal peptide, EGF repeats of the extracellular domain of human Notch3receptor protein, wherein at least 12 EGF repeats are present, and an Fcportion of an antibody bound thereto.
 5. The fusion protein of claim 1,wherein the Fc portion of the antibody is the Fc portion of a humanantibody.
 6. The fusion protein of claim 1, wherein the signal peptideis the signal peptide of Notch3 or IgG Heavy Chain.
 7. The fusionprotein of claim 1, wherein the extracellular domain of Notch1 receptorprotein comprises EGF-like repeats 1-34.
 8. The fusion protein of claim1, wherein the fusion protein comprises consecutive amino acids, thesequence of which is set forth in any of SEQ ID NOs:32, 33, 31, or 34.9-11. (canceled)
 12. A method for treating a subject having a tumorcomprising administering to the subject an amount of the fusion proteinof claim 1 effective to treat the subject, thereby treating the subjecthaving a tumor.
 13. A method for inhibiting angiogenesis in a subjectcomprising administering to the subject an amount of the fusion proteinof claim 1 effective to inhibit angiogenesis in the subject, therebyinhibiting angiogenesis in the subject.
 14. A method for treating asubject having ovarian cancer comprising administering to the subject anamount of the fusion protein of claim 1 effective to treat the subject,thereby treating the subject having ovarian cancer.
 15. A method fortreating a subject having a metabolic disorder comprising administeringto the subject an amount of the fusion protein of claim 1 effective totreat the subject, thereby treating the subject having a metabolicdisorder. 16-18. (canceled)
 19. A method for inhibiting physiologicallymphangiogenesis or pathological lymphangiogenesis in a subjectcomprising administering to the subject an amount of the fusion proteinof claim 1 effective to inhibit physiological lymphangiogenesis orpathological lymphangiogenesis in the subject.
 20. (canceled)
 21. Amethod of inhibiting tumor metastasis in a subject comprisingadministering to the subject an amount of the fusion protein of claim 1effective to inhibit tumor metastasis in the subject.
 22. (canceled) 23.A method of inhibiting growth of a secondary tumor in a subjectcomprising administering to the subject an amount of the fusion proteinof claim 1 effective to inhibit growth of the secondary tumor in thesubject.
 24. (canceled)
 25. A method of inhibiting blood vessel cooptionby a tumor in subject comprising administering to the subject an amountof the fusion protein of claim 1 effective to inhibit blood vesselcooption by a tumor in the subject.
 26. A method of treating cancer in asubject comprising administering to the subject the fusion protein ofclaim 1 and an inhibitor of Vascular Endothelial Growth Factor (VEGF),each in an amount effective to treat the cancer in the subject. 27.(canceled)
 28. A method of treating cancer in a subject comprisingadministering to the subject the fusion protein of claim 1 and a VEGFreceptor inhibitor, each in an amount effective to treat the cancer inthe subject.
 29. (canceled)
 30. A method of treating cancer in a subjectcomprising administering to the subject the fusion protein of claim 1and an inhibitor of Platelet Derived Growth Factor (PDGF), each in anamount effective to treat the cancer in the subject.
 31. (canceled) 32.A method of treating cancer in a subject comprising administering to thesubject the fusion protein of claim 1 and a PDGF receptor antagonist,each in an amount effective to treat the cancer in the subject. 33.(canceled)
 34. A method of treating cancer in a subject comprisingadministering to the subject the fusion protein of claim 1 and aninhibitor of HER2/neu, each in an amount effective to treat the cancerin the subject.
 35. A method of treating breast cancer in a subjectcomprising administering to the subject an amount of the fusion proteinof claim 1 effective to treat the breast cancer in the subject. 36.(canceled)